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INTRODUCTION 
 
 
Introduction 
 
Human cytomegalovirus (HCMV) is one of the members of the Herpesviridae family and 
is a very common cause of human infection. The seroprevalence for the disease ranges 
from 50% among adults in United States to 90% among children of 4 years of age in 
India (1,2). However, the virus remains in equilibrium with the host immune system and 
disease manifestations are very rare in a healthy individual infected with the virus. 
Serious morbidity and mortality is seen in individuals with immature immunity such as 
neonates, and in individuals with compromised immunity such as solid organ and bone 
marrow transparent recipients (3).  
Bone marrow transplantation is one of the treatment modalities for malignancies or 
abnormalities of the lymphohematopoietic system (4). Bone marrow transplant patients 
undergo immunosuppressive therapies to increase their chances of successful engraftment 
which leads to increased risk of developing opportunistic infections. Cytomegalovirus 
(CMV) infections form  the major viral opportunistic infection in bone marrow transplant 
patients that manifest at 40-50 days after transplantation (5). After engraftment, the rate 
of incidence of active CMV infection is approximately 60–70% in CMV seropositive 
patients and CMV seronegative recipients‟ with grafts from seropositive donors. If no 
preventive measures are taken, approximately 20–30% of these patients progress to CMV 
disease (6). Since most of the patients already have a latent infection with 
cytomegalovirus even before the transplantation, they remain at risk of reactivation of the 
infection and thereby manifesting the disease. Although patients can be treated with the 
antiviral drug ganciclovir, the prognosis for patients who have already manifested 
symptoms of the disease, even with treatment, is poor (7,8). One approach to the problem 
is by initiating pre-emptive therapy for which the patient is started on ganciclovir when 
there are indications of an impending viral infection. The importance of starting 
preemptive therapy at the most appropriate time cannot be overemphasised as initiation 
of therapy too early can lead to unnecessary exposure of the patient to ganciclovir, a bone 
marrow toxic drug, while delay in initiation of therapy can lead to non-response to 
therapy. 
 One of the indicators of an impending infection is CMV DNA levels in the blood of the 
patient (9). CMV DNA monitoring provides several advantages over the conventional 
method of quantitating pp65 antigenemia, such as faster turn over time, less hands-on 
work with more convenient work techniques and minimal  inter- observer variability  in 
experienced hands (10). CMV DNA monitoring was also found to be a more accurate 
method for detection of CMV levels than monitoring pp65 antigenemia  (11). However 
no consensus has been reached on the CMV DNA threshold level at which treatment 
should be initiated. There is wide variation in the cutoff levels from centre to centre as 
different methods of CMV DNA quantitation are employed in each centre. Moreover, the 
geographical variations in the CMV seroprevalence rates also call for an individualized 
estimation of threshold levels. 
Another approach to determining the onset of CMV disease is quantitation of CMV 
mRNA as it has been found to be a sensitive indicator of viral replication (12). Detection 
of CMV transcripts in peripheral blood indicates that the virus is undergoing replication, 
and hence, it is likely that the patient has CMV disease.  
The aim of this study was to measure the CMV viremia levels in blood by quantitating 
both CMV DNA and CMV Immediate Early (IE) - mRNA and comparing their levels to 
determine an appropriate threshold for initiation of pre-emptive therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
 
AIM AND OBJECTIVES 
 
 
AIM: To study the kinetics of CMV viremia in bone marrow transplant patients (BMT) 
undergoing CMV reactivation in the early post- transplant period. 
 
OBJECTIVES: 
 
1. To evaluate the kinetics of CMV DNA levels in BMT patients who reactivate 
CMV within the first 12 weeks post- transplant (by serial monitoring with real-
time PCR). 
 
2. To quantitate the CMV IE-mRNA levels in blood samples of BMT patients using 
real-time reverse transcriptase PCR (RT-qPCR) in the post-transplant period. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
REVIEW OF LITERATURE 
 
1. Human cytomegalovirus 
1.1 CMV infection  
Primary human CMV infection is usually asymptomatic in an immunocompetent 
individual. Infection can also result in a mononucleosis syndrome, with fever, myalgia, 
lymphadenopathy, and hepatomegaly (13,14). However, CMV is capable of causing 
serious morbidity and mortality in neonates whose immune system is still immature. It is 
the leading infectious cause of neurological abnormalities and deafness in children, who 
were infected with the virus in utero (15,16). Another group of individuals who develop 
severe manifestations with CMV infection are the immunocompromised, such as people 
infected with human immunodeficiency virus and transplant recipients (17). 
1.2 HCMV infection in haematopoeitic stem cell transplant patients 
CMV infections form the major viral opportunistic infection in bone marrow transplant 
patients that manifest at 40-50 days after transplantation (5).The most common 
manifestations of the disease are pneumonitis and gastrointestinal disease (colitis) (18). 
After engraftment, the rate of incidence of active CMV infection is approximately 60–
70% in CMV-seropositive patients or CMV-seronegative recipients who receive 
transplants from a seropositive donor. If no preventive measures are taken, approximately 
20–30% of these patients progress to CMV disease (6).  
 
2. Properties of HCMV: 
 
2.1 Classification and taxonomy 
CMV is referred to officially as Human herpesvirus 5, and belongs to the Herpesviridae 
family. Herpes viruses are classified into alpha, beta and gamma types based on their 
biological characteristics, genomic organization, tissue tropism, and amino acid identities 
(19). CMV along with Human herpesvirus 6 and 7 are classified as betaherpesviridae 
because of their long replicative cycle and restricted host range. The other members of 
the family include the human pathogens Human herpesvirus 1, 2 and 3 (with the common 
names of herpes simplex types 1 and 2 and varicella-zoster virus) which belong to 
alphaherpesviridae while Human herpesvirus 4 (Epstein-Barr virus) and Human 
herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) belong to the 
gammaherpesviridae. The alphaherpesviridae members are characterised by their short 
cell cycle along with cytolytic properties. The gammaherpesviridae show variable cell 
cycles and exhibit a tropism for lymphoid tissue. 
CMV was discovered in 1956 and was so named for the enlargement of the host cells 
after infection with the virus (20). The characteristic enlarged cells along with the 
inclusion bodies were observed by scientists even before the discovery of the virus. In 
1881, Ribbert visualized the enlarged cells in kidney and parotid gland tissue sections of 
children. Jesionek and Kiolemenoglou, who had also made the same observation, had 
come to the conclusion that the intracytoplasmic inclusions could be protozoa. In 1932, 
Wyatt suggested the name “generalized cytomegalic inclusion disease (CID)” for 
children affected by a congenital disease with presenting clinical signs of petechiae, 
intracerebral calcifications and hepatosplenomegaly. In 1956 Wellers, Smith and Rowe 
were independently able to grow and isolate the virus on human cell lines. In the same 
year, the virus was given the name cytomegalovirus by Thomas Wellers (21). 
2.2 Structure of CMV 
CMV is a double stranded DNA virus falling in Class 1 of the Baltimore classification 
(22). The virus has the largest genome among the herpes viruses with approximately 235 
kilo base pairs encoding for 165 genes (23). The DNA is enclosed in an icosahedral 
capsid of 162 capsomers with a diameter of 110 – 125 nm. The nucleocapsid is composed 
of five herpesvirus core proteins (24). Outer to the nucleocapsid is a protein covering also 
called the tegument or matrix. The tegument contains the majority of the viral proteins 
along with some amount of cellular and viral RNA. The proteins present in the tegument 
play a role in maintaining the structure of the virus, aiding in its disassembly and 
assembly inside the host cell and also help in regulating the host immune response in an 
infection (24).  
Mature virions have a diameter of approximately 200 – 300 nanometers and are 
completely enclosed in a lipid bilayer envelope that is derived from the host cell 
endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC). The envelope 
contains approximately 20 virus-encoded glycoproteins that play a major role in cell 
attachment and penetration (24). Virion envelope glycoprotein B (gB) is responsible for 
cell attachment and penetration while glycoprotein H (gH) is necessary for fusion of viral 
envelope with host cell membrane (24).   
Structure of HCMV 
 
 
2.3 Viral Genome 
The CMV genome has the distinction of being the largest genome among the herpes 
viruses infecting humans. It is a linear double stranded DNA molecule comprising 236 
kilo base pairs. The genome is arranged into a unique long (UL) and a unique short (US) 
sequence flanked by terminal and inverted repeats. The terminal repeat long (TRL) and 
the internal repeat long (IRL) flank the UL region while the internal repeat short (IRS) 
and the terminal repeat short (TRS) flank the US region (25).  
The genome encodes for approximately 166 genes including a single oriLyt and two 
transcriptional enhancers, one within the UL and one within the US region (24). The 
relatively high number of genes results in a crowded genome and the virus compensates 
for this bulky gene size by incorporating complex transcriptional processes. Some of 
them are described below: 
a. Multiple transcripts that have the same initiation point and promoter but 
different termination points (26). 
b. Multiple transcripts that have the same terminal points with the benefit of 
common poly-A signal and poly–A site but with different initiation sites 
(26). 
c. Transcripts that can undergo complex differential splicing by removing 
differing intron regions to produce multiple final products (26). 
d. Sense and antisense transcript pairs that are generated from complementary 
strands when read in opposite directions (26). 
 
 
  
 
 
2.3.1 Structure of the immediate early gene 
The immediate early gene is the first gene to be expressed during productive primary 
infection and also in reactivation after a latent infection (24). The major immediate early 
genes are located at the UL122-123 region of the CMV genome. Alternative splicing of 
transcripts has been extensively employed by the virus at this site and this generates a 
Schematic representation of HCMV genomic organization and open reading frames. Courtesy : 
Dunn W, Chou C, Li H, Hal R. Functional profiling of human cytomegalovirus genome. Proc 
Natl Acad Sci U S A.2003 Nov 25 
wide variety of transcripts some of which do not yet have any functions assigned to them 
to date. The UL123 region encodes for 4 exons and the most important product from this 
region is the 72-kDa major IE protein, IE72. Other minor transcripts derived from 
differential splicing of the same produce the proteins IE19, IE17.5 and IE9.The IE2 is 
represented immediately after the IE1 region at UL122. The major protein products from 
this region are IE86 followed by IE18 and IE55 (27).  
2.4 Viral replication 
The virus particles can be detected in various body fluids such as urine, saliva and breast 
milk during an active infection as well as during recovery from an infection indicating 
that the virus is capable of division in a variety of host cells. However, studies on the 
viral replication and other features are conducted in viruses that are passaged on 
fibroblasts (24). The virus interacts with host cell surface heparan sulphate and binds to 
it, following which the viral envelope fuses with the cellular membrane. This releases the 
nucleocapsid into the cellular cytoplasm (28). The cellular cytoskeleton then translocates 
the nucleocapsid to the nuclear membrane where interaction with the nuclear pores 
releases the viral DNA  into the nucleus of the cell (29).  
During replication, there is a highly coordinated expression of genes in the virus with the 
immediate early, delayed early and late proteins generated in sequence. This temporal 
cascade of viral gene expression is initiated with the transcription of immediate early 
genes promptly after viral entry as it does not depend on expression of any other viral 
gene. The immediate early proteins have profound effects on the host cells by 
suppressing pathways that initiate interferon activation and disintegrating the major 
histocompatibility complex (MHC)-1 antigen presentation. This leads to some protection 
of the infected cells from the deleterious effects of cell mediated immune response of the 
host. These result in a conducive environment for the virus to replicate  and the 
subsequent expression of the delayed early and late genes (30).  
The delayed early proteins are reponsible for viral DNA replication and the late genes 
code for viral structural proteins. Viral DNA synthesis is initiated in productive infection 
of a cell with a gradual increase in DNA synthesis. Immediate early transactivators 
initiate transcriptional activation of orilytA region that is responsible for DNA 
replication. Viral DNA undergoing replication circularizes and replication follows a 
rolling circle mechanism. The proteins responsible for DNA synthesis are segregated in 
regions of the cellular nucleus called replication compartments which are seen as the 
classic intranuclear inclusions of  CMV infected cells (31).  
Viral DNA encapsidation occurs in the nucleus with a procapsid shell formed from five 
herpesvirus conserved proteins. Encapsidation of DNA and maturation of procapsid to 
nucleocapsid is enabled by a number of proteins, of which the most important is the 
maturational protease, also called assemblin (24).  
The most popular theory regarding egress and release of virion particles is the 
envelopment/deenvelopment/reenvelopment process (32). As the nucleocapsid matures, it 
is released from the nucleus into the cytoplasm. During this process, a primary 
envelopment occurs at the inner nuclear membrane followed by a deenvelopment at the 
outer nuclear membrane. During its course through the cytoplasm, the nucleocapsid 
acquires the proteins that form the tegument. The secondary envelopment occurs at the 
endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membranes (33). After 
final envelopment, the virion is incorporated into a vesicle and fusion of this exocytic 
vesicle with the plasma membrane releases the progeny virus into the extracellular space. 
The distinctive cytoplasmic inclusion body that is seen in an infected cell is the expanded 
endoplasmic reticulum and Golgi complex within which the nucleocapsids accumulate 
before their egress from the cell. This inclusion deforms the host cell nucleus giving it a 
kidney bean appearance, while the entire cell assumes an owl‟s eye appearance on 
visualization under the light microscope (24).  
2.5 Latency and reactivation 
CMV is capable of persisting in a latent form in an immunocompetent host following 
which periodic reactivation occurs under conditions are favorable for virus replication.  
The exact site of latency of the virus is not definitively known. However some evidence 
of presence of genomic viral DNA in cells of myeloid lineage suggests that they could 
harbor the virus during periods of latency (34). The cell lineages implicated are the 
monocytes/macrophages (35), lymphocytes (36), CD34
+ 
bone marrow cells (37), 
immature dendritic cells (38) and endothelial cells (39). Viral DNA is present in very low 
copy numbers in such cells, (2 to 13 copies per cell) making it difficult to detect the virus 
in a state of latency (40). The latency state is maintained by the transcriptional repression 
of the major Immediate Early promoter (41). Immunosuppression, inflammation, 
infection and stress can trigger  reactivation of CMV (42). Chemical mediators like 
Tumor necrosis factor α, proinflammatory prostaglandins and stress catecholamines can 
initiate transcription of CMV immediate early genes via cellular mediators, thereby 
promoting viral replication (43–45).  
2.6 Immune responses to the virus 
2.6.1 Innate immunity 
The innate immune system plays a vital role in the body‟s defense against 
cytomegalovirus. Stimulation of toll like receptors (TLRs) by the antigens such as gB/ gH 
present on the viral envelope leads to production of inflammatory cytokines, generation 
of alpha/beta interferon by dendritic cells and macrophages, and upregulation of co-
stimulatory molecules like CD80 and CD86 that trigger adaptive immunity (46,47).  It 
has been demonstrated that natural killer cells play a major role in recovery from CMV 
infection in renal transplant patients (48). 
2.6.2 Adaptive immunity 
2.6.2.1 Humoral immunity 
Neutralizing antibodies produced against the virus restrict its dissemination in the human 
body and reduce the severity of the illness in susceptible individuals. Most neutralizing 
antibodies are produced against conformational epitopes formed by the gH/gL/UL128-
131A complex that mediates entry of the virus into various host cells (49,50). In humans, 
transfer of anti-CMV antibodies from mother to new born infant protects the neonate 
from infection with the virus (51). 
2.6.2.2 T-cell mediated immune responses 
Cell mediated immunity is the essential arm of immunity against CMV; severity of 
illness in patients with compromised cellular immunity adding further evidence to this. 
However, even though the various components of cellular immunity (CD8
+
 T cells and 
CD4
+
 T cells) are able to contain the virus, it not sufficient to completely eradicate the 
virus from the body.  
Studies conducted in mice with selective depletion of lymphocyte subsets have revealed 
that CD8
+
 T lymphocytes play the major role in immunity mounted against murine 
cytomegalovirus (MCMV). An integral role of CD8
+
 T cells in cellular immunity in bone 
marrow transplant patients was demonstrated by studies conducted by Riddell et al in 
1992 and Walter and colleagues in 1995. They successfully transferred CMV-specific 
CD8
+
 T cells to bone marrow transplant patients and observed that cellular immunity 
against CMV was effectively restored with no significant toxicity generated against the 
cells (52,53). UL123 (IE1), UL 122 (IE2) and UL83 (pp65) are the most 
immunodominant regions, to which the CD8
+
 T cells mount an active response. 
Approximately 10% of CD8
+ 
T cells in the peripheral blood of healthy virus carriers are 
dedicated as anti CMV response.  This subset expands and accumulates to form 40% of 
the CD8
+
T cell pool in the elderly age group and this phenomenon has been termed 
“memory inflation” (54). This clonal expansion of cells may contribute to the immune 
senescence in old age where the subset of naïve T cells is less compared to the younger 
age group (55). It also hinders the response to other pathogens and maybe a cofactor that 
enhances progression to AIDS in  HIV co-infected individuals (56).  
CD4
+
 T cell response is also essential for generating protective immunity against CMV. 
Relatively, 9.1% of the total CD4
+
 T cell population in an adult is primed to respond to 
CMV and the major immunodominant region for this subset of cells is the viral gB (57). 
CD4
+ 
T cells provide immunity by sustaining the antibody production, maintaining and 
reconstituting  CD8
+
 T cells and killing virus-infected cells by releasing enzymes like 
granzyme B (58).  
2.7 Immune evasion by CMV 
Although the immune system of an immunocompetent person is able to protect them 
from active infection by CMV, it is not adept at clearing the virus from the body or 
eradicating the state of viral latency. This characteristic exhibited by the virus may be due 
to  various immune evasion tactics employed; these properties have been studied in  
murine cytomegalovirus and mouse models (59).  
2.7.1Effect on Natural Killer cells 
Viral UL40 protein enhances expression of HLA-E on the cell surface and this in turn 
inhibits NK cells (60,61). The virus produces UL18 which is structurally similar to the 
MHC Class 1 receptor that inhibits NK cell activity; UL18 also has higher affinity for the 
inhibitory NK cell receptor, LILRB
+ 
(62,63). In addition, UL83, UL141, UL16, UL112-1 
and UL142 have been proven to cause  down-regulation of the NK cell signaling 
pathways, thereby rendering them immunologically incompetent (64–68).  
2.7.2 Effect on CD8
+
 T Cells 
Activation of CD8
+
 T Cells is down-regulated by CMV by reducing the expression of 
MHC Class 1 on the surface of infected cells. This is achieved by the highly coordinated 
expression and action of viral proteins after infection. Viral gene products of UL2 and 
UL11 degrade the heavy chains of newly synthesized MHC Class 1 proteins (69). MHC 
Class 1 peptide complexes are retained in the endoplasmic reticulum by US3 of the virus 
and peptide translocation of the same is inhibited by US6 (70,71).  
2.7.3 Effect on CD4
+
 T Cells 
Similar to the mechanism of MHC Class 1 downregulation, MHC Class 2 is suppressed 
in order to curb the immunogenicity and activation of CD4+ T Cells. US2 of the virus 
reverts HLA-DRα and HLA-DMα to the cytoplasm where it is degraded (72). In addition, 
it has been demonstrated that the protein transcribed by UL111 is structurally similar to 
the inflammatory cytokine IL10 (and thus named cmvLA IL10). This protein plays 
multiple roles in down-regulating the MHC Class 1 and 2 expression, suppressing 
peripheral blood monocytes, and interrupting the production of inflammatory cytokines 
(73–75). 
In addition, infected cells express a cell surface glycoprotein which acts as an Fc 
receptor. This causes nonspecific binding of Fc portion of immunoglobulins to the cell 
surface, thus masking the infected cell from the host‟s immune system. 
2.8 Pathology and clinical presentations of CMV infections 
The spectrum of clinical presentation of CMV infections is varied and depends mainly on 
the age and immune status of the individual.  
2.8.1 Congenital and perinatal infections 
A mother acquiring a primary infection or undergoing reactivation of latent infection 
during pregnancy can transmit the virus to the fetus via the placental system. Congenital 
infection can cause death of the fetus in utero in approximately 20% of cases. In 
cytomegalic inclusion disease of newborns, the central nervous system and 
reticuloendothelial systems are the most severely affected. The major manifestations 
include intrauterine growth retardation, retinitis, microcephaly, thrombocytopenia, 
jaundice and hepatosplenomegaly. Around 95% of children born to mothers who have a 
recurrent infection with the virus are asymptomatic, with 7% to 25%  presenting late in 
life with deafness and learning deficiencies (76).  
2.8.2 Healthy adolescents and adults 
Primary infection with CMV in immunocompetent adults is usually asymptomatic. A 
small proportion of individuals may present with symptoms resembling infectious 
mononucleosis which rarely requires therapy since most spontaneously recover (77). 
However, there have been case reports of immunocompetent individuals with primary 
CMV infection presenting with end-organ disease such as hepatitis, meningitis, 
encephalitis, nerve palsies and Guillian-Barre syndrome (78,79).  
2.8.3 Immunocompromised hosts 
2.8.3.1 HIV infected individuals 
CMV posed a significant threat to persons infected with HIV before the introduction of 
highly active anti-retroviral therapy (HAART). Patients with a CD4
+
 count of 100 and 
below were most at risk of infection with CMV. However with the introduction of 
HAART, the incidence of CMV disease has drastically dropped in this population (80).  
The most common manifestation of disease in these individuals is hemorrhagic retinitis 
with necrosis. Some  other presentations  include esophagitis, gastritis, enterocolitis, 
pneumonitis, hepatitis and immune recovery vitritis with posterior segment inflammation 
seen in patients who are started on HAART (81).  
2.8.3.2 Solid organ transplant patients 
CMV is a one of the major pathogens causing considerable damage in the post- transplant 
period in individuals who have received a solid organ transplant. More than 50% in this 
group develop symptoms of the disease with features such as febrile neutropenia, 
pneumonitis, enterocolitis, gastritis, hepatitis, retinitis and other end organ disease 
(82,83). CMV infection can also cause graft rejection (84–86), renal artery stenosis in 
renal transplant patients (87), bronchiolitis obliterans in lung transplant patients and 
rapidly progressing coronary artery stenosis in patients with heart transplant  (88,89). 
CMV infection has also been implicated in the increased predisposition to other 
opportunistic bacterial and fungal pathogens in this group (90). 
2.8.3.3 Hematopoietic stem cell transplant patients 
The prolonged immunodeficiency required in this group of individuals puts them at risk 
of reactivation and primary symptomatic infection with CMV. The details of the 
infections are discussed below.  
2.9 Epidemiology of CMV infections 
Although CMV infections are common throughout the world, geographical variations in 
seroprevalence do exist. Seroprevalence based on anti-CMV IgG antibodies also depends 
on the age group, socioeconomic status, and parity (91).  
Several studies conducted in women of the reproductive age group around the world 
reveals high seroprevalence rates among women in South America, Africa and Asia, with 
the lowest rates recorded in Western Europe and United States of America. A study 
conducted by Sheevani et al in the northern states of India found statistically significant 
difference in the seroprevalence between women from rural compared to urban areas. 
They have reported a higher incidence of circulating antibodies in women from rural 
areas, living in poor socioeconomic conditions and poor hygiene. Another observation 
was the higher seroprevalence noted in the women of higher parity as compared to 
nulliparous women. This could be attributed to child-to-mother  transmission (92).An 
Indian study conducted by Venkitaraman et al in South India has shown that 90% of 
children are seropositive for CMV by the time they reach 4 years of age (2). The higher 
seroprevalence in the low socioeconomic status may be attributed to higher population 
density arising from the higher number of children per family (since crowded living 
conditions allow better transmission of the virus easier) and the low standards of hygiene. 
3. Hematopoietic stem cell transplantation (HSCT) 
3.1 Introduction to bone marrow transplantation 
Bone marrow transplantation (BMT) is one of the treatment modalities for malignancies 
or abnormalities of the lymphohematopoietic system and has evolved to become the 
standard of care in many hematological malignancies. Conditions where BMT plays a 
crucial role in treatment are diseases of bone marrow inadequacy like aplastic anemia, 
malignancies (leukemias), lymphomas, hemoglobinopathies, multiple myeloma, severe 
immunodeficiency syndromes, inborn errors of metabolism (e.g.chronic granulomatous 
disease) and high-risk solid organ disease like neuroblastoma (18). The procedure 
involves the transfer of hematopoietic cells from a donor to a recipient who has 
undergone a conditioning regimen that enables them to accept the transplanted cells. 
3.2 Types of HSCT 
HSCTs can be classified into allogeneic and autologous transplants based on the source 
of the donor cells. In autologous transplants, the cells are harvested from the patient, 
which are later re-infused into the same patient after high dose myeloablative therapy, in 
preparation for the transplant. Syngeneic transplants are very similar to autologous 
transplants in that an HLA identical twin is the donor. Such transplants are most 
commonly used in diseases like breast cancer, Hodgkins lymphoma and non Hodgkins 
lymphoma (93). The advantages of this procedure are the low risk of development of 
graft versus host Disease (GVHD) and faster immunological recovery. However, they are 
at risk of a relapse from the graft if tumor cells contaminate the stem cell transplant (94).  
In allogeneic transplants, the cells are harvested from a donor other than the transplant 
recipient. This procedure is used in conditions like aplastic anemia and chronic 
myelogenous leukemia. Sources of stem cells for such candidates include HLA matched 
siblings, family members or unrelated members who can be accessed through registry 
organizations such as (DATRI) that maintain computerized databases of HLA types of 
voluntary donors. Compared to autologous transplants, these patients are at a higher risk 
of GVHD, graft rejection and delayed immunological recovery (95).  
3.3 Immune system and opportunistic infections before and after HSCT 
3.3.1 Immunity during the conditioning regimen 
The normal process of hematopoiesis generates viable neutrophils, monocytes and 
macrophages and this process is destroyed during the conditioning regimen. Mucosal 
progenitor cells are wiped out leading to a temporary loss of mucosal barrier immunity. 
Hence, commensal bacteria and fungi that are lodged in the gastrointestinal tract, skin 
and other mucosae then become potential pathogens.  T lymphocytes and B lymphocytes 
(primed to antigen exposure from natural infections, vaccines and environmental 
antigens) and memory cells generated over the lifetime of the patient are entirely 
obliterated, rendering the patient immunologically defenseless.  
3.3.2 Pre-engraftment, Engraftment and Post-engraftment 
The pre-engraftment period is defined as the time period from the start of conditioning to 
20-40 days in the immediate post-transplant period. The patient is at risk of bacterial 
infections with the depletion of neutrophils and obliteration of the mucosal barrier. 
Failure of neutrophil recovery by day 42 is considered to be graft failure (18). 
Engraftment is defined as the time at which a patient can maintain a constant absolute 
neutrophil count of more than 500/mm
3 
and a sustained platelet count of more than 
20,000 cells/mm
3
, for more than at least three consecutive days without transfusions (96). 
Engraftment occurs at around the 22
nd
 day in the post-transplant period for unrelated 
allogeneic transplants, and almost always  within a range of 6 to 84 days (97). The post-
engraftment period is marked by the recovery of neutrophils lasting upto the 100
th 
day 
after transplantation. The late risk period is taken as the time period after day 100 till the 
time the patient regains normal immunity, which can last from 18-36 months after 
transplantation (98).  
After neutrophil recovery, monocytes and Natural Killer (NK) cells recover followed by 
platelets and red blood cells. Lymphocytes are the last set of cells to recover, beginning 
with NK cells, followed by CD8
+
 T cells. B lymphocytes recover later while CD4
+
 T 
cells take the longest time to recuperate.  
Regeneration of lymphocytes can follow two distinct pathways and the process is 
inefficient, making the recovery process slow. In one pathway, lymphocytes, mainly NK 
cells and B lymphocytes, regenerate from bone marrow lymphoid progenitor cells, 
thereby creating a naïve immune system similar to that of young children. Also, the 
specialized marrow microenvironment called the „bursal equivalent‟ (essential for B cell 
regeneration) is highly sensitive to the toxic effects of the conditioning regimen, GVHD 
or treatment undertaken for the same. Hence, B cells take longer to regenerate than NK 
cells (99). 
Complete reconstitution of humoral immunity requires the generation of memory B cells. 
These cells are produced on re-exposure to either environmental antigens or vaccines. 
The entire process, which also requires the help of CD4
+
 T cells, takes upto a year for full 
recovery. For these reasons, the patient remains susceptible to infections from 
encapsulated bacteria and viruses during the first year after transplantation, as the 
essential mode of defense against these organisms are neutralizing antibodies (99).  
Regeneration of T cells occurs through an expansion of T cells present in the graft that 
responds to T cell deficiency in vivo. This is a thymic independent pathway as opposed to 
the normal development of T cells in healthy individuals, and is termed „homeostatic 
peripheral expansion‟. A combination of factors drives this process, including increase in 
cytokines like IL-7 and IL-15, release of inflammatory cytokines during tissue damage 
during the preparative regimen, and exposure to viral antigens. Regeneration of CD8
+
 T 
cells is more efficient than that of CD4
+
 T cells, resulting in a higher CD8/CD4 ratio for 
several months after transplantation (99).  
Although it is imperative that all HSCT patients undergo immunosuppression for 
successful engraftment, the severity of the immunosuppression and recovery of the 
immune system post-transplant depend on a number of factors. Some of these factors 
include the development of GVHD, recipient factors like age, co-morbidities, and 
exposure to infectious agents (99).  
 
 
 
 
 
Approximate immune cell counts before and after myeloablative HSCT. 
Courtesy:Mackall C et al. Background to hematopoietic stem cell transplantation, 
including post transplant immune recovery. Bone Marrow Transplantation.2009; 44: 
457–462 
3.3.3 Infections following HSCT 
Opportunistic infections affecting HSCT patients can be classified into three phases 
depending on the immune status of the patient 
3.3.3.1 Phase 1: Pre-engraftment phase  
The factors that predispose to infections in this period are prolonged neutropenia, 
mucosal barrier breaks and the intermittent use of vascular catheters for patient care. The 
most common pathogens seen in this phase are bacterial organisms followed by Candida 
and Aspergillus spp (96). 
3.3.3.2 Phase 2: Post-engraftment phase 
During this phase, the patient has deficient cell mediated immunity resulting in a higher 
risk for infections due to herpes viruses like cytomegalovirus, Pneumocystis carinii and 
Aspergillus spp (96). 
3.3.3.3 Phase 3: Late phase 
During this phase, the patient has deficient cell mediated immunity and humoral 
immunity along with impaired reticuloendothelial cell functions. The predominant 
pathogens during this phase are cytomegalovirus, varicella zoster virus, Epstein Barr 
virus, community acquired respiratory viruses and encapsulated bacteria like 
Haemophilus influenzae and Streptococcus pneumoniae (96). 
 
  
 
 
 
 
 
 
Phases of immune system recovery and opportunistic infections among HSCT 
patients. Courtesy:Mackall C et al. Background to hematopoietic stem cell 
transplantation, including post transplant immune recovery. Bone Marrow 
Transplantation.2009; 44: 457–462 
 
4. CMV infections in HSCT recipients 
4.1 Factors affecting development of CMV infection in HSCT patients 
4.1.1 CMV Serological status of recipient and donor 
CMV serological status of both the recipient and donor influence the development of 
CMV disease in the post-transplantation period. If the recipient is seronegative, care 
should be taken to select a donor who is also seronegative. Transplant-related mortality is 
lowest when a CMV seronegative recipient receives stem cells from a donor who is also 
CMV seronegative (100). If the recipient is seropositive or if a seronegative recipient is 
infused with cells from a CMV seropositive donor, the risk of CMV disease reaches 60-
70%. If no preventive measures are taken, approximately 20–30% of these patients 
progress to CMV disease (6).The higher risk of developing CMV disease with a donor 
positive/recipient negative situation may be attributed to the indirect immunomodulatory 
effects of CMV as these patients were shown to have a higher incidence of bacterial and 
viral diseases in the post-transplant period, as shown by Nichols et al (101). 
The transplant related mortality outcome as a result of having a CMV seropositive donor  
has been controversial. Some studies have suggested that transplantation of CMV 
seropositive recipients with CMV seropositive unrelated donors had better outcomes with 
higher event-free survival rates and reduced transplant related mortality (102). A 
megafile analysis by Ljungman et al from data of the European Group for Blood and 
Marrow Transplantation (EBMT) registry provides results that corroborate this finding. 
The study also concluded that patients who received grafts from a seronegative donor had 
an increased risk of death. One of the possible mechanisms suggested for this negative 
interaction is lack of transfer of CMV specific effector T lymphocytes (103). However 
this observation is debatable and the findings were not reproduced in other studies (104).  
4.1.2 Effect of source of stem cells and CD34 selection 
Studies have shown that transplants conducted with unrelated or mismatched related 
donors have a higher rate of development of CMV disease and transplant related 
mortality (105,106). Similarly, umbilical cord blood transplant recipients are at a higher 
risk of CMV disease if they are not started on appropriate antiviral prophylaxis (107). 
Reconstitution of CMV specific T cells occurs much faster with autologous HSCT. Even 
though these patients may show a short-lived phase of viral replication, they rarely 
progress to CMV disease; there is thus no need to start antiviral therapy in such patients 
(108,109). 
While CD34 depletion  theoretically  removes contaminating tumor cells from the graft, it 
is associated with higher rates of CMV disease in both allogeneic and autologous 
transplant patients undergoing myeloablative conditioning regimen (110).  
4.1.3 Effect of immunosuppression in the post-transplantation period 
An immunosuppressive regimen is administered post-transplantation to prevent rejection 
of the graft and avoid complications from development of GVHD. Treating patients with 
mycophenolate mofetil, high dose corticosteroids( >1mg/kg/day), Alemtuzumab(anti-
CD52 monoclonal antibody) (111), antithymocyte globulin and use of T cell-depleted 
allografts and autografts, are considered  high risk factors for the development of CMV 
disease (112,113).  
The severity of immunosuppression determines the time it takes for the immune system 
to recover, and hence it has an indirect effect on the replication dynamics of the virus. 
Hence, in severely immunocompromised recipients, the viral load doubles in 24 hours as 
shown by studies conducted by Emery et al (114).  
4.2 Clinical manifestations of CMV disease 
CMV disease can present as either early disease occurring within the first 100 days 
following transplantation or late disease manifesting after 100 days. The most common 
presentations of early disease are gastrointestinal disease affecting the gastrointestinal 
tract anywhere from the oesophagus to the colon, interstitial pneumonia affecting the 
lungs and hepatitis (6). During the late phase, CMV disease can manifest as CMV 
retinitis or affect the central nervous system (115,116). These manifestations can also be 
termed as the direct effects of CMV infection. Some of the definitions associated with 
CMV disease are: 
CMV infection is defined as detection of the virus, viral proteins or nucleic acid in any 
body fluid or tissue specimen (117). 
Primary CMV infection is defined as the detection of CMV in a previously CMV 
seronegative individual (117). 
Recurrent infection is defined as new detection of CMV infection in a patient who has 
been previously documented to have infection and who has not had virus detected for at 
least 4 weeks of active surveillance. Recurrent infection can be a reactivation of latent 
virus (endogenous) or reinfection (exogenous) (117). 
CMV disease is defined as detection of CMV by immunohistochemical analysis of 
biopsy specimens followed by clinical signs and symptoms, such as unexplained fever (> 
38°C), leucopenia (white blood cells < 3.5 × 10
9
/L) and/or thrombocytopenia (platelet 
count < 100 × 10
9
/L), gastrointestinal symptoms, arthralgia, hepatitis, enteritis, retinitis, 
pneumonitis, colitis, oesophagitis and  encephalitis (118). 
The most serious manifestation of CMV disease is interstitial pneumonia and 
approximately half the patients with this complication succumb to it (119). It manifests as 
fever, nonproductive cough and hypoxia. Fever may not be present in patients who are 
subjected to high degrees of immunosuppression (120). CMV gastroenteritis presents as 
ulcers of the gastrointestinal tract which may extend into the submucosal layer. 
Indirect effects of CMV infection in HSCT patients include graft rejection and 
superinfection with bacteria and fungi due to further weakening of the patient‟s immunity 
(101,121). 
 
 
 
5. Diagnosis of CMV infection and disease 
Patients selected for an HSCT should undergo serological evaluation of anti-CMV IgM 
and IgG antibodies to determine their serostatus. This is also applicable for the donor 
whose serostatus is a definite predictive indicator for the development of CMV disease in 
the post-transplant period. However the use of serological indicators for evaluation of 
CMV disease in the post transplant period is controversial. Although some clinicians do 
not deem serological indicators to be of any value in diagnosing CMV disease (120), 
there have been contradicting studies conducted on the efficacy of determination of rising 
titres of anti-CMV IgG as well as detection of anti-CMV IgA and IgM. These studies 
have pointed out that serological indicators may be used as a marker of CMV reactivation 
in the post transplant period especially in laboratory settings where PCR and antigenemia 
tests are unavailable (122,123).  
In the event of CMV end organ disease, a diagnosis can be established by  virus isolation 
and culture from samples representing the diseased organ, in situ DNA hybridization, 
direct fluorescent antibody tests or immunohistochemistry (117). Diagnosis of end organ 
disease like pneumonia and gastrointestinal disease by molecular techniques such as PCR 
for CMV DNA may be too sensitive and interpretation of results may not be conclusive 
as silent reactivation of the virus can happen in these tissues without causing disease. 
Hence PCR is not a useful test for diagnosis end organ disease and may be used only 
when suspecting CMV encephalitis, a rare entity (117,124) 
 
5.1 Viral isolation and culture 
CMV culture is done on fibroblast cell lines derives from human embryonic tissue, 
foreskin tissue and human foetal lung tissue. Patient samples such as urine and blood can 
be inoculated on these cell lines. The virus is detected by determining the cytopathic 
effect (CPE) which includes enlargement of the host cell, with intranuclear inclusions. 
The day of appearance of CPE varies with the virus titre in the sample. High titre samples 
may yield results in 24 – 48 hours. Culture results may be delayed for upto 6 weeks for 
low titre samples (125). Detection of the virus on cultures can be improved by using 
immunoflouresence techniques like employment of monoclonal antibodies against viral 
antigens. The turnaround time of viral culture can be enhanced by techniques such as 
shell vial culture on coverslips and centrifugation to enhance viral uptake on cell lines 
(126,127).  
 Quantitation of virus in culture can be achieved by plaque assay and titre determination 
(50% tissue culture infective dose or TCID50). The plaque assay is performed by infecting 
fibroblast monolayers with serial dilutions of the specimen and overlaying this with a 
semisolid medium. The monolayers are incubated at 37
o
Cand the reading is taken by 
counting the numbers of infectious plaques formed in each dilution under the microscope 
(128). For determination of TCID50, fibroblasts monolayers are inoculated with serial 
dilutions of the specimen and readings taken after 3-6 weeks. The virus titre is estimated 
by determining the highest dilution that produces a cytopathic effect in 50% of inoculated 
cell cultures. Shell vial culture uses fibroblast cell culture monolayers on a coverslip and 
centrifugation of sample onto the monolayer to enhance recovery rate and reduce the 
recovery time of cultures. Although viral cultures do not require sophisticated laboratory 
techniques or equipment, it is still a time consuming procedure with low sensitivity (129). 
Detection of early antigen immunoflourescent foci (DEAFF) is a rapid culture based 
diagnostic assay that employs antibodies against viral antigen to detect viral growth on 
shell vial cultures after 16-24 hours of incubation (130,131). However, culture based 
techniques may not yield reliable results in transplant patients as drugs such as 
antibiotics, antifungals, cytotoxic agents and immunomodulators may be toxic to cell 
lines used for  cultures (132). 
5.2 pp65 antigenemia assay 
The assay utilizes monoclonal antibodies directed against pp65(UL83) to detect and 
quantitate CMV infected peripheral blood polymorphonuclear leukocytes(PMNL) (133). 
The PMNLs are separated from the patient‟s blood sample using dextran and fixed onto 
slides using chemicals such as acetone, formaldehyde-Nonidet P-40 etc. The cells are 
counted and treated with monoclonal antibodies. The slides are then viewed using a 
flourescence microscope and the number of cells that flag positive are counted. This test 
does not require highly sophisticated laboratory facilities and yields faster results than 
cell culture. It has also been demonstrated in comparison studies that the levels of 
antigenemia correlate well with CMV DNA levels in plasma and leukocytes.  However, 
the cell counting process is laborious and there may be inter observer variability in 
determining the result (129).  
5.3 Molecular assays for quantification of CMV 
5.3.1 Branched-DNA Signal amplification assay 
The branched DNA (bDNA) signal amplification assay can be performed on blood, CSF 
and semen samples directly. For blood samples, leukocytes are separated using dextran 
and lysed using Proteinase K to release nucleic acid. The lysate is then allowed to react 
with CMV specific target probes bound to a 96 well microtitre plate for 16 – 18 hours. 
The bDNA amplifier molecules (that have approximately 45 sites for binding of alkaline 
phosphatase labeled probes) are then added. The signal is read using a luminometer after 
allowing the enzyme alkaline phosphatase to react with a chemiluminescent substrate. 
Quantification is done by comparison with a standard curve (134). There are only a few 
reports on the performance of this assay. As there is no amplification of DNA in this 
procedure, there is very little chance of cross contamination. However, the long 
incubation step increases the turnaround time for the results (129).  
5.3.2 Hybrid capture CMV DNA assay 
This test is performed on leukocytes separated from whole blood. After lysis, the released 
DNA is allowed to react with CMV specific RNA probes that are complimentary to 
approximately 17% of the viral genome. The RNA-DNA complex is then immobilized 
using antibodies specific to the complex which is then tagged with antibodies labeled 
with alkaline phosphatase and a chemiluminescent substrate (135). The advantages of the 
test include the lack of an amplification step or prolonged incubation. A newer second 
generation assay also claims to have a lower limit of detection of 700 copies of genome 
per ml of whole blood. However, comparison studies with the antigenemia assay and 
quantitative DNA PCR assays show conflicting reports, with some assays concluding that 
the assay is inferior to both the other tests (136,137).  
5.3.3 Quantitative CMV DNA PCR 
The quantification of nucleic acids using PCR is based on the formula Y = X (1+E)n 
where Y stands for the amount of DNA obtained after amplification with PCR, X is the 
quantity of target DNA before amplification, E is the efficiency of the PCR reaction and 
n is the number of cycles of amplification. The quantity of amplified DNA is estimated 
by comparing it with a standard curve that is derived by amplification of known 
quantities of target DNA (129).  
Real time PCR using Taqman probes quantitates the amount of DNA accumulating in 
each cycle at the same time as the amplification process (that is, in real time). This 
alleviates the need for post PCR processing and allows for earlier issue of reports. 
Taqman probes have sequences that are complimentary to the target DNA and contain a 
reporter dye and quencher dye. The proximity of the reporter dye and quencher prevents 
the reporter dye from emitting a signal. As the amplification proceeds, Taq polymerase 
cleaves the reporter dye from the probe, thus removing it physically away from the 
quencher molecule. The reporter dye thus emits a signal that is detected by the machine 
and with each cycle of amplification, the increase in intensity is measured to give an 
estimate of the final DNA concentration (138).  
Real time PCR for CMV DNA can be carried out on whole blood, plasma, leukocytes 
separated from whole blood, CSF, and other samples. Systemic viral load can be 
estimated using whole blood, plasma or leukocytes. Since the virus is usually associated  
with the cellular fraction, quantitative PCR for DNA would be higher if performed on 
whole blood or leukocytes than plasma. However studies have established that the DNA 
estimates from that of plasma correlate well with that of whole blood or buffy coat (139).  
5.3.4 Quantitative CMV mRNA estimation  
Although CMV antigenemia testing and DNA detection are convenient methods of 
detection of the virus, a positive result need not indicate an active infection in the patient.. 
Detection of CMV transcripts in peripheral blood indicates that the virus is undergoing 
replication, and hence the possibility that the patient may have CMV disease cannot be 
ruled out. IE mRNA is detected within one hour of active infection of a cell and RNA of 
late structural proteins such as pp67 or pp150 can also be looked for (12). Using reverse 
transcriptase enzyme, mRNA is converted into complimentary DNA (cDNA) followed 
by amplification with PCR. However, the major concern of such a test was the 
contamination of the RNA extracts with CMV DNA which yielded false positive results. 
In order to circumvent this disadvantage, several techniques were employed such as 
treating the nucleic acid extract of the sample with DNase enzyme and designing primers 
flanking the intron region. However, even these techniques suffered setbacks when 
DNase failed to completely remove the contaminating DNA and some of the transcripts 
did not have any introns or splicing mechanisms. Nucleic acid sequence based 
amplification was a novel technology introduced in 1991 in which RNA can be amplified 
even with contaminating DNA (140). The technology employs the use of the enzymes 
avian myeloblastosis reverse transcriptase, RNase H and T7 RNA polymerase. It is an 
isothermal amplification technique with amplification occurring at 41ºC. Contaminating 
DNA does not interfere in this process as the process of DNA amplification in this 
process is highly inefficient (141).  
6. Treatment of CMV disease 
Intravenous ganciclovir is the drug of choice for treatment of CMV disease (142). 
Ganciclovir is a nucleoside analogue and has to undergo phosphorylation by viral and 
cellular kinases for activation. After activation, ganciclovir triphosphate binds to viral 
DNA and causes premature termination of chain synthesis. It is also an inhibitor of viral 
DNA polymerase enzyme. Valganciclovir is the prodrug of ganciclovir and has tenfold  
higher oral bioavailability than ganciclovir (143). The disadvantages of using ganciclovir 
are the development of neutropenia and emergence of drug resistance (144,145). Patients 
undergoing treatment with ganciclovir should be carefully monitored for neutropenia 
with absolute neutrophil count checks, at least twice a week (146). 
Foscarnet, a pyrophosphate analog, is the second line drug recommended in case 
resistance develops to ganciclovir. It acts by binding on the pyrophosphate binding site of 
CMV DNA polymerase and preventing its activity (143). The administration of foscarnet 
is associated with significant renal toxicity and electrolyte imbalances such as 
hypocalcemia, hypomagnesemia and hypophosphatemia (18). Hence the patient should 
be prehydrated before administering the drug and continuously monitored for electrolyte 
imbalances. 
CMV gastroenteritis is treated with ganciclovir or foscarnet alone. Duration and dosing 
of therapy depends on the extent of disease and depth of ulcers. Induction therapy can last 
for 2-3 weeks followed by several weeks of maintenance dosing. Since CMV pneumonia 
has higher mortality rates and is difficult to treat, a combination therapy of intravenous 
ganciclovir or foscarnet along with intravenous immunoglobulin is suggested (147).  
Treatment of concurrent conditions such as GVHD and optimal supportive therapy with 
proton pump inhibitors is also critical in recovery.  
7. Prevention of cytomegalovirus disease 
7.1 Prevention of primary CMV infection 
If a patient is seronegative for CMV before transplantation, care should be taken to 
prevent CMV infection both before and after transplantation. The patient should be 
transfused only with either blood products from CMV seronegative donors or leukocyte-
depleted filtered blood products. In such patients, selecting a donor who is CMV 
seronegative is an important screening criterion and holds as much importance as finding 
an appropriate HLA match (120).  
 
 
7.2 Prevention of CMV reactivation or infection  
7.2.1 Choice of donor 
The choice of an appropriate donor to be selected for a recipient who is CMV 
seronegative is debatable. Several studies have shown that transfusing such patients with 
cells from CMV seropositive donor is protective for the patient with better survival rates 
(102). Also it has been shown that patients receiving cells from CMV seronegative 
donors had increased rates of CMV reactivations and disease (148).  
7.2.2 Antiviral chemoprophylaxis 
Drugs such as high dose acyclovir, valacyclovir (which is a prodrug of acyclovir with 
better oral bioavailability) and ganciclovir have been administered as prophylactic agents 
in HSCT patients who are at high risk of developing CMV disease. Although prophylaxis 
with ganciclovir was highly effective in reducing incidence of CMV disease, it was 
associated with a number of other adverse events. Ganciclovir, being a potentially 
marrow toxic drug, can itself cause neutropenia which in turn predisposes the patient to 
other invasive bacterial and fungal infections (149,150). In order to prevent the 
neutropenia, growth factors can be administered to the patient. However, this adds to the 
cost of an already expensive procedure. Also the subset of patients, who may never 
develop the disease, would be given a marrow toxic drug unnecessarily.  
 
 
7.2.3 Preemptive therapy and viral load monitoring 
Another approach to the prevention of disease is by preemptive therapy, wherein 
ganciclovir therapy is instituted upon detection of increasing levels of CMV in blood(an 
indicator of active viral infection (9). The goal of initiating preemptive therapy is to 
prevent the development of disease in patients. Hence, the window period at which this 
therapy is initiated is crucial. Emery et al have shown in a study that the initial viral load 
and the rate of increase in viral load are important predictors of impending CMV 
infection (114). 
CMV DNA detection by quantitative real time PCR is the most commonly used method 
used for monitoring CMV levels in the patient‟s blood.  When compared to pp65 
antigenemia, CMV DNA quantification by PCR offers the benefits of increased 
sensitivity for detection of reactivation of CMV, reduced time to perform the procedure, 
reliable results even with severe neutropenia in the early post-transplant period and 
ability to process large numbers of specimens at a time (10). DNAemia is also a more 
accurate indicator of actual viral replication in vivo than antigenemia (11). Preemptive 
therapy can be initiated when a certain viral load threshold is crossed or when the rate of 
increase of CMV DNAemia over time is significant, hence avoiding unnecessary 
treatment of patients who may not progress to disease (147). Although there are several 
studies from around the world that suggest DNA cutoff values at which pre-emptive 
therapy can be started, they cannot be used as standard cutoff values as they utilize 
different primer sets, target sequences and extraction and detection methods. 
In a study conducted by Emery et al, the average doubling time of CMV was found to be 
only 1 to 2 days and that the in vivo replication dynamics depended on the degree of 
immunosuppression (114). Although the initial viral load is a good predictor for the risk 
of CMV disease, the viral load increases may also provide potential grounds for initiating 
preemptive therapy. When monitoring viral load, the variability inherent to the assay 
should be considered before setting a cutoff for initiation of therapy, to ensure only 
patients with “true increases” are given therapy. Since the coefficient of variation of most 
molecular assays that detect DNA approaches  30% near the limit of detection, only 
increases of more than 0.5log10 rise should be considered an indicator for preemptive 
therapy (10,129,147).  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
MATERIALS AND METHODS 
Study design: 
This is an observational study conducted in the patients undergoing hematopoietic stem 
cell transplantation in the Department of Hematology, Christian Medical College, Vellore 
and the diagnostic tests for CMV were conducted in the Department of Clinical Virology.  
Study duration: 
The study was conducted over a period of 17 months from April 2012 to August 2013 
Recruitment of study subjects 
Inclusion Criteria:  
1. Patients undergoing bone marrow transplant at our centre  
2. Patients who reactivate CMV within first 100 days following BMT 
Exclusion Criteria:  
1. Patients who do not consent to the study 
2. Patients who reactivate beyond 100 days following BMT 
 
 
 
 
Sample collection for CMV DNA PCR: 
Patients were enrolled after taking appropriate consent. Blood samples were collected from 
the patients once a week for the first three weeks after transplantation till engraftment. 
Thereafter from week 4 to week 12, blood samples were taken biweekly. 5-6 ml of blood 
was collected in 6ml K2EDTA BD vacutainer tubes (BD Biosciences). The samples were 
transported in ice to the Department of Clinical Virology. The samples were stored at -
20ºC as two aliquots of 200µl and 1ml in 1.7ml micro centrifuge tubes.  
Sample collection for CMV mRNA RT-PCR: 
Quantitation of the IE-mRNA was performed only retrospectively after the patients 
reactivated for HCMV. Therefore there was the need to store these samples in RNA 
LATER solution (Qiagen, Hilden, Germany). However RNA LATER solution cannot be 
used for preservation of RNA in whole blood as the solution forms insoluble complexes 
with plasma. Hence the samples were stored as peripheral blood mononuclear cells 
(PBMCs), as RNA LATER can be used for the preservation of RNA in lymphocytes. 
PBMCs were separated from whole blood using Ficoll-Paque Plus (GE healthcare, 
Uppsala, Sweden). Ficoll-Paque is based on the principle of density gradient separation. 
When whole blood is centrifuged with Ficoll-Paque the red blood cells aggregate at the 
bottom of the tube followed by the granulocytes. The Ficoll-Paque with a density of 1.099 
forms a transparent layer above the granulocytes, thus separating the lymphocytes, 
monocytes and platelets. These three cells form a layer between the Ficoll-Paque and 
plasma. The cells are carefully retrieved and washed several times to yield pure PBMCs. 
The PBMCs were stored in RNA LATER as two aliquots of 200µl at -80ºC in 1.7ml micro 
centrifuge tubes. 
 
 
 
Schematic representation of time period of collection of samples 
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The different layers formed after centrifuging whole blood with Ficoll-Paque. 
Courtesy: Munoz et al. Highly purified selective isolation of eosinophils from human 
peripheral blood by negative immunomagnetic selection. Nature Protocols 2007 
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Patient recruited into study after consent is taken in 
the Department of Hematology (n=162) 
Whole blood samples collected in 6ml EDTA 
Vacutainer tubes at appropriate time 
periods(n=2467) 
Samples aliquoted as Whole blood and PBMCs and 
stored in the Department of Clinical Virology 
Patients who reactivated for CMV DNA were 
selected (n=35) 
Patients with satisfactory set of samples were 
selected (n=25) 
Serial CMV DNA testing done by real time PCR for 
the selected 25 patients 
Primers, probe for the IE-mRNA RT-qPCR 
designed using Primer 3 software for the 72 kDa  
splice variant of IE-mRNA region 
 
CMV IE-mRNA testing done by reverse 
transcriptase real time PCR during the periods of 
reactivation 
Separation of PBMC using Ficoll-Paque: 
Materials required: 
15 ml centrifuge tubes with conical bottom (Tarson products. Kolkata, India) 
Ficoll-Paque plus (GE healthcare, Uppsala, Sweden) 
Phosphate buffer solution (PBS) [pH: 7.2 – 7.4] 
1000µl long reach pipette tips 
Centrifuge with swing buckets 
Procedure: 
1. Label five centrifuge tubes with the sample number. 
2. Mix the blood sample well and pipette 3ml of whole blood into the centrifuge tube. 
Dilute the blood with 6ml PBS. Mix well to dilute the sample. 
3. Pipette out 3ml of Ficoll-Paque into 3 separate centrifuge tubes. 
4. Carefully layer 3ml of the diluted blood sample onto the Ficoll-Paque in the three 
separate centrifuge tubes using the 1000µl reach pipette tips. 
5. Centrifuge the centrifuge tubes at 2000 rpm for 30 minutes at 20ºC.  
6. After centrifugation, three separate layers comprising of RBC at the bottom, Ficoll-
Paque and plasma at the top are obtained. The PBMC are seen as an interphase between the 
Ficoll-Paque and plasma layer. 
7. Carefully remove the plasma layer without disturbing the cells above the Ficoll-Paque. 
Aspirate the cells from all three centrifuge tubes and place them in a new centrifuge tube. 
8. Centrifuge the aspirate at 2000rpm for 10 minutes.  
9. Discard the supernatant. Add 5ml of PBS. Mix well and centrifuge at 2000rpm for 10 
minutes. 
10. Discard the supernatant. Add 1.5ml of PBS, mix well and centrifuge again at 2000rpm 
for 10 minutes. 
11. Discard the supernatant. The washed cells are mixed in 400µl of PBS. 
12. The cells are stored as two aliquots of 200µl mixed with 200µl of RNA Later at -80ºC. 
Preparation of phosphate buffered saline  
Materials required: 
NaCl                            8gm 
KCl                              0.2gm 
Na2HPO4                           1.15gm 
KH2PO4                       0.2gm 
Distilled water             1000ml 
Procedure 
1. Dissolve the salts in distilled water and make up the volume to 1000ml. 
2. Adjust the pH to 7.4 with 1N NaOH. 
3. Autoclave at 121ºC for 15 min at 15lb. 
4. The autoclaved solution is stored at 4ºC. For every use PBS is diluted with sterile MilliQ 
water to a dilution that is one in tenth of the original concentration. The pH is checked and 
adjusted before every use. 
Designing of primers and probes for CMV mRNA RT-PCR 
The target RNA selected for reverse transcriptase PCR was the Immediate Early-1 mRNA. 
The gene sequence for the same was retrieved from the nucleotide blast on Pubmed.org. 
The primers were designed using the free online software Primer 3. The primers were 
ordered from Sigma-Aldrich, Bangalore, India. 
Reconstitution of primers and probes 
Two sets of primers and probes were ordered for the standardization of mRNA quantitative 
real time reverse transcriptase PCR. The primers and probes were reconstituted with Tris 
EDTA buffer. The quantity of buffer to be added for the reconstitution was given in the 
manufacturer‟s instruction. After reconstitution the final concentration of the primers and 
probes was 100pmol/µl. The reconstitution of the primers was carried out in a biosafety 
cabinet after wiping the surfaces with alcohol and RNase Away solution.  
The final quantity of the aliquots and the number of aliquots of the primers and probes 
were calculated. Appropriate numbers of 0.6ml microtubes were labeled with the details of 
the primers and probes. The tubes were then placed under UV light for 30 minutes inside a 
biosafety cabinet. The primers and probes were then aliquoted into these microtubes. The 
microtubes were then placed in a cryobox and stored at -20ºC until further use. 
CMV DNA PCR: 
The CMV DNA was extracted from whole blood aliquots and real time quantitative PCR 
was performed on the Rotor-Gene 3000 thermal cycler (Corbett Research, Sydney, 
Australia). The gene targeted for the DNA PCR is the immediate early gene. The primers 
designed for the PCR target a 150 base pair region of this gene. The lower limit of 
detection of the assay was already determined to be 100 copies/ml and the assay was 
standardized in the Department of Clinical Virology for routine testing.  
DNA extraction protocol 
Materials required 
Qiamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) containing: 
QIAamp Mini Spin Columns 
Collection Tubes (2 ml)  
Buffer AL 
Buffer AW1 
Buffer AW2 
Buffer AE 
Proteinase K 
1.7 ml micro centrifuge tube 
Handcare gloves, Mask 
Plastic apron 
Biosafety cabinet 
Procedure: 
1. Add 20µl of Proteinase K to 200µl of the sample in a 1.5ml of micro centrifuge tube. 
2. Add 200µl of Buffer AL to the sample. Mix well by pulse-vortexing for 15 seconds. 
3. Incubate the above mixture at 56ºC for 10 minutes in a dry bath. 
4. Centrifuge the sample for a brief time to remove the moisture on the lids. 
5. Add 200µl of 100% ethanol to the sample and mix well by pulse-vortexing for 15 
seconds. 
6. Centrifuge the sample to remove the moisture from the inside of the lids. 
7. Transfer the above mixture to a Qiagen Mini spin column which is placed on a 2ml 
collection tube. 
8. Centrifuge the Mini spin column at 8000rpm for one minute.  
9. The flow through along with the collection tube is discarded and the mini spin column is 
placed on a fresh collection tube. 
10. Add 500µl of buffer AW1 to the mini spin column and centrifuge the sample at 
8000rpm for one minute. 
11. Discard the collection tube with the flow through. Transfer the mini spin column onto a 
fresh collection tube. 
12. Add 500µl of AW2 buffer to the spin column and centrifuge this at 14,000 rpm for 3 
minutes. 
13. Discard the collection tube with the flow through. Transfer the mini spin column onto a 
fresh collection tube and centrifuge at 14,000 rpm for 1 minute at 4ºC. 
14. Discard the collection tube and place the mini spin column in a 1.5ml micro centrifuge 
tube. Add 200µl of elution buffer AE to the spin column and incubate at room temperature 
for one minute. 
15. Centrifuge the above at 8000rpm for one minute.  
CMV DNA Real time PCR 
Materials required: 
Qiagen Norox mastermix buffer (Qiagen, Hilden, Germany) 
Nuclease free water 
Forward primers 
Reverse primers 
Taqman probes 
Cooling block 
Pipette 
Pipette tips 
Handcare gloves 
Biosafety cabinet 
Dirty room 
Procedure: 
The concentrations of the different components of the PCR mix for one reaction are given 
below: 
Reagents Quantity(µl) 
Qiagen Norox mastermix buffer 12.5 
Forward primer 0.075 
Reverse primer 0.075 
Taqman probes 0.05 
Nuclease free water 2.7 
DNA extract 10 
Total volume 25 
 
1. The mastermix is prepared for the appropriate number of reactions with the above 
template. The mastermix is prepared in the clean room.  
2. Appropriate number of 0.5ml PCR tubes were labeled appropriately. 
3. 15µl of the freshly prepared mastermix was aliquoted to the PCR tubes. The PCR tubes 
are kept on the cooling block. 
4. The DNA extract is added to the appropriately labeled PCR tubes in the dirty room. The 
extracts are added in a biosafety cabinet without light or air currents as the probes are light 
sensitive. 
5. The tubes are loaded into the Rotor-Gene 3000 thermal cycler (Corbett Research, 
Sydney, Australia) which is kept in another room.  
6. The cycling conditions for the reactions are as follows: 
CYCLE TEMPERATURE(ºC) TIME 
HOLD 95 15 minutes 
CYCLING (50 cycles) 95 45 seconds 
60 75 seconds 
 
The total time required for the completion of the run is 160 minutes. 
The quantitation of the DNA was performed using in house standards prepared by cloning. 
The internal control used for the extraction procedure and the PCR conditions was the 
amplification of the GAPDH gene. The cycling conditions for the amplification of the 
GAPDH gene were similar to that for the amplification of the CMV DNA PCR. 
 
 
 
 
 
CMV mRNA RT-qPCR: 
The 72 kDa splice variant of the IE-mRNA was the target for the RNA PCR. The RNA 
was extracted from the PBMC stored at -80ºC.  
RNA extraction protocol 
Materials required: 
Qiagen Rneasy minikit (Qiagen, Hilden, Germany) containing: 
RNeasy Mini Spin Columns 
Collection Tubes (1.5 ml) 
Collection Tubes (2 ml) 
Buffer RLT 
Buffer RW1 
Buffer RPE 
RNase-Free Water 
70% Distilled water 
Pipette (100 - 1000µl) 
Pipette (20 - 200µl) 
Pipette tips 
Hand care gloves, Surgical mask 
Plastic apron 
Centrifuge 
Vortex 
Biosafety cabinet 
Procedure: 
The Qiagen RNeasy minikit was used for extraction of RNA from the PBMC samples. The 
method as recommended by the manufacturers was followed for the extraction process.  
1. The PBMC sample is thawed at 4ºCelsius. 
2. 600µl of RLT buffer is added to the microtube containing the PBMC sample. This is 
vortexed and centrifuged. 
3. One volume of 70% ethanol is added to the microtube. The sample is mixed by pipetting 
and centrifuging should be avoided in this procedure. 
4. Transfer 700µl of the sample to an RNeasy minispin column and centrifuge at 9500rpm 
for 15 seconds. The flow through is discarded and the 2ml collection tube is reused. The 
remaining sample is transferred to the spin column and centrifuged at 9500 rpm for 15 
seconds.  
5. 500µl of RPE buffer is added to the spin column and the spin column is centrifuged at 
9,500 rpm for 15 seconds. The flow through is discarded and the collection tube is reused. 
6. 500µl of RPE buffer is again added to the spin column and centrifuged at 9,500 rpm for 
2 minutes. The flow through and collection tube are discarded. 
7. The spin column is transferred to a new 2ml collection tube and centrifuged at 13,500 
rpm for 1 minute.  
8. The spin column is transferred to the 1.5ml microtube. 50µl of RNase free water is 
added to the spin column. This is centrifuged at 9,500 rpm for 1 minute. This step elutes 
the RNA. 
DNase treatment of RNA 
Materials required: 
DNAse enzyme with buffer 
EDTA 
0.5 ml microtubes 
Procedure: 
1. 1µl of DNase enzyme is mixed with 1µl of the buffer in a 0.5ml microtube tube. This 
step is carried out in the clean room. 
2. 8µl of the RNA extract is added to the above mixture. 
3. The mixture is incubated at 37ºC for 30 minutes in a thermal cycler. 
4. The DNase enzyme is inactivated by adding 1µl of EDTA and incubating at 65ºC for 10 
minutes in a thermal cycler. 
5. The DNAse treated RNA can be used for reverse transcriptase PCR. This pretreatment 
step ensures that the DNA present in the sample does not give a false positive result with 
reverse transcriptase PCR. 
Reverse transcriptase PCR 
Materials required 
Qiagen One step RT PCR Kit (Qiagen, Hilden, Germany) 
Nuclease free water 
Forward and reverse primers, probes 
Cooling block 
Pipette, pipette tips 
Procedure 
The concentrations of the different components of the PCR mix for one reaction are given 
below: 
Reagents Quantity (µl) 
One step RT-PCR mastermix 12.5 
Reverse transcriptase enzyme 0.25 
Forward primer 0.15 
Reverse primer 0.15 
Probe 0.1 
Nuclease free water 1.85 
DNase treated RNA extract 10 
Total volume 25 
 1. The mastermix is prepared for the appropriate number of reactions with the above 
template. The mastermix is prepared in the clean room.  
2. Appropriate number of 0.5ml PCR tubes are labeled. 
3. 15µl of the freshly prepared mastermix is aliquoted to the PCR tubes. The PCR tubes are 
kept on the cooling block. 
4. The RNA extract is added to the appropriately labeled PCR tubes in the dirty room.  
5. The tubes are loaded into the Rotor-Gene 3000 thermal cycler (Corbett Research, 
Sydney, Australia).  
6. The cycling conditions for the reactions are as follows: 
CYCLE TEMPERATURE(ºC) TIME 
HOLD 1 (cDNA conversion) 45 15 minutes 
HOLD 2 95 10 minutes 
CYCLING X 45 CYCLES 95 25 seconds 
53 30 seconds 
72 60 seconds 
 
The total reaction takes approximately 180 minutes to complete. 
The quantitation of the mRNA was performed using inhouse standards produced by 
cloning. 
The internal quality control used for the PCR is the Endogenous retrovirus (ERV3) RNA. 
ERV3 standards were used for quantitation of the cells present in the sample based on the 
principle that every human cell has two copies of ERV3.  
Determination of the limit of detection of the CMV IE-mRNA RT PCR assay 
The lower limit of detection of the assay was determined by replicate testing of serial 
dilutions of the known standards used for quantitation. The lowest dilution standard (S5) 
for the assay contained 30,000 copies/ml. The standards were serially diluted so as to 
obtain 1/10, 1/100 and 1/1000 dilutions of S5. The copy numbers in the corresponding 
dilutions were 3000 copies/ml, 300 copies/ml and 30 copies/ml. The dilutions were then 
tested in triplicates on three separate days. The minimum concentration of the copies 
detected was then calculated and an average of the copies was taken to determine the lower 
limit of detection of the assay.  
 
ERV3 RT-qPCR 
The RNA extract used for the CMV mRNA estimation was used for the quantitation of 
ERV3. The real time quantification of ERV3 RNA was done using the two step reverse 
transcriptase method. After DNase treatment the extract was used for cDNA conversion. 
The cDNA was then used for real time quantification. 
 
 
cDNA conversion of ERV3 RNA 
The following template was used for cDNA conversion of ERV3: 
Reagent Amount(µl) 
5x buffer 4 
dNTP 0.8 
Random primer 2 
0.1 M DTT 2 
RNase Out 0.5 
MMLV Reverse Transcriptase enzyme 0.2 
MilliQ water 0.5 
DNase treated RNA 10 
Total volume 20 
 
1. The mastermix is prepared for the appropriate number of reactions with the above 
template. The mastermix is prepared in the clean room.  
2. Appropriate number of 0.5ml PCR tubes is labeled. 
3. 15µl of the freshly prepared mastermix is aliquoted to the PCR tubes. The PCR tubes are 
kept on the cooling block. 
4. The RNA extract is added to the appropriately labeled PCR tubes in the dirty room. The 
extracts were added to the PCR tubes in a biosafety cabinet with the light and air current 
switched off.   
5. The PCR tubes are then loaded on the ABI Veriti thermal cycler (Applied Biosystems, 
Foster City, CA, USA), which is kept in another room. 
The temperature settings for the cDNA conversion are as follows: 
Cycle Temperature(ºC) Time(minutes) 
Hold ( cDNA conversion) 37 60 
Stop ( Termination of enzyme activity) 95 5 
  
The resulting cDNA was subjected to real time PCR. The template used for the PCR is as 
follows: 
Reagents Quantity(µl) 
Qiagen Norox mastermix buffer 12.5 
Forward primer 0.075 
Reverse primer 0.075 
Taqman probes 0.05 
Nuclease free water 2.7 
cDNA extract 10 
Total volume 25 
 
1. The mastermix was prepared for the appropriate number of reactions with the above 
template. The mastermix is prepared in the clean room.  
2. Appropriate number of 0.5ml PCR tubes are labeled. 
3. 15µl of the freshly prepared mastermix was aliquoted to the PCR tubes. The PCR tubes 
are kept on the cooling block. 
4. The DNA extract is added to the appropriately labeled PCR tubes.  
5. The tubes are loaded into the Rotor-Gene 3000 thermal cycler.  
The cycling conditions for the PCR are given below: 
Cycle Temperature(ºC) Time 
Hold 1 45 15 minutes 
Hold 2 95 10 minutes 
Cycling (50 cycles) 95 25 seconds 
56 30 seconds 
72 60 seconds 
 
The reaction takes approximately 150 minutes to complete.  
The quantitation of ERV3 was done using in-house standards for ERV3. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
RESULTS 
Sample collection: 
The study was initiated in July, 2012 after appropriate clearance was obtained from the 
Institutional Review Board of the college. A total of 162 patients were enrolled into the 
study from July, 2012 to September, 2013. Informed consent was taken from all patients 
before enrolling into the study. 132 patients were followed up completely for a period of 
100 days in the post-transplant period. A total of 2467 samples were collected from all 
the study patients and all the samples were stored as four aliquots. The patient 
compliance regarding the sample collection is depicted in the following graph: 
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Figure 1: Graph depicting the patient compliance in sample collection. 
All 21 samples were collected from 25 patients, who form 15.4% of the study group. 
Only 38 patients gave less than 10 samples for the study and most of them were recruited 
in the later part of the study where follow up for 100 days was not possible.  
 The samples were transported at 4ºC to the Department of Clinical Virology in 
containers with ice packs. The samples were processed on the same day of collection. In 
the laboratory, each patient was allotted a study number (eg: CS1) and four 1.7ml micro 
centrifuge tubes were labeled with the study number as well as the day of collection of 
that sample. Two aliquots of 1ml and 200µl of whole blood were stored in the micro 
centrifuge tubes at -20ºC. The rest of the sample was used to separate PBMCs using the 
Ficoll-Paque based density gradient separation technique. After the PBMCs were 
separated, it was stored in RNA LATER solution at -80ºC as two aliquots. 
Demographic data for 162 patients: 
Age: The age groups of the patients ranged from 1 year to 63 years. 77 patients (47.5%) 
of the patients belonged to the pediatric age group with ages ranging from 1 to 15 years.  
Sex: Out of 162 patients, 52 were female patients and 110 were male patients. 
 Primary diagnosis: 
The patients enrolled into the study underwent HSCT for malignant and non-malignant 
causes.  
 
The major non-malignant condition for which HSCT was performed was for thalassemia 
major while the major malignant condition was acute myeloid leukemia.  
Age
1 -15yrs
16 - 60 yrs
more than 60 
yrs
Sex
Female
Male
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Primary diagnosis
Thalassemia major
Acute myeloid leukemia
Aplastic anemia
Acute lymphocytic leukemia
Fanconi anemia
Myelodysplastic syndrome
Lymphoma
Type of transplant: 
The source of stem cells for the graft can be a sibling, an unrelated donor (allogeneic) or 
the patient itself (autologous). All allogeneic sources undergo HLA typing and matching 
with the recipient. In the event of no matched donors, a haploidentical graft can be taken 
from a donor. 
 
Matched unrelated donors formed 75.3% of the donor group. The other major group of 
donors was the matched sibling donors who formed 19.7% of the group.  
Graft source: 
Stem cells can be harvested from the peripheral blood (PBSCT) or the bone marrow 
(BMT).  
32
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Type of transplant
Matched sibling donor
Matched unrelated donor
Autologous graft
Haploidentical graft
The source of the graft for the patients in the study group is represented in the graph 
below. 
 
CMV Serostatus: 
The CMV serostatus of all patients was determined by measuring their CMV IgG 
antibodies just before transplantation. 
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The CMV serostatus of the patients reflects the epidemiology of the virus in the Indian 
subcontinent. Only 4.9% of the study population was not exposed to the virus; the 
majority (95%) of the study group had been exposed to the virus before the 
transplantation.  
CMV DNA testing: 
 Reactivation of CMV in the post-transplant period was determined by CMV DNA levels 
monitored by real time quantitative PCR. Routine testing for CMV DNA is performed on 
the samples of these patients if there is clinical suspicion of the disease or as routine 
twice or thrice in the post-transplant period. As part of the study, the weekly samples 
from all patients were stored at -20ºC. The patients who reactivated for CMV had CMV 
DNA levels more than 1000copies/ml. These patients were then selected and their 
samples were retrieved from storage and CMV DNA PCR was performed on them later.  
Rate of reactivation: 
Thirty five of the 162 patients (21.6%) reactivated during the course of the study. The age 
groups ranged from 2 to 50 years. 16 patients (45.7%) were in the pediatric age group, 
between 2 and 15 years. The reactivators comprised 11 female patients and 24 male 
patients.  
 
 
The primary diagnosis of the reactivators, the type of donor and the graft source is 
depicted in the charts below: 
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CMV Serostatus of reactivators: 
Of the 35 patients, 33 tested negative for CMV IgM and positive for CMV IgG, 
indicating past exposure to HCMV and a possible latent status of the virus in these 
patients. Only two patients tested negative for both CMV IgM and CMV IgG indicating 
that the patients did not have an exposure to the virus before transplantation. 
 
CMV DNA Serial monitoring: 
25 patients, who had a complete set of samples, were selected from the reactivators and 
serial DNA monitoring was undertaken for these patients. The samples of these patients 
were taken out of the freezer and thawed and CMV DNA PCR was conducted on these 
samples.  
 
 
33
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CMV Serostatus of reactivators
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IgM neg, IgG neg
Comparison of presenting CMV DNA values and peak CMV DNA values: 
Serial CMV DNA values of all the patients were measured and graphs were plotted for 
each individual patient.  
 
 
 
 
Out of 25 patients who were serially monitored for CMV DNA, 24 patients had CMV 
DNA values that were low at the time of presentation with higher values of DNA 
appearing later during the reactivation. One patient had the highest DNA values at the 
time of presentation. 
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Figure 2: Graph comparing the CMV DNA values at presentation and peak CMV 
DNA values of reactivators. 
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Figure 3: Graph depicting the day of CMV reactivation of patients in the 
post-transplant period 
Figure 4: Graph depicting the number of patients showing reactivation at 
various time intervals  
Twelve of 25 patients (48%) of the study group reactivated on Day 30 in the post-
transplant period while5 (20%) of them reactivated on Day 23. 2 patients (8%) 
reactivated in the pre engraftment period at Day 10. 23 patients (92%) reactivated in the 
engraftment period which has been established to be the time period in the post-transplant 
period when patients are most susceptible to CMV reactivation with the virus. This has 
been attributed to the poor cell mediated immunity seen in patients during the period.  
Comparison of peak CMV DNA levels in reactivators: 
The peak CMV DNA values of all the patients are represented in the following graph. 
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Figure 5: Graph depicting the peak CMV DNA values of all reactivators. 
Of 25 patients, 7(28%) consistently showed CMV DNA values below 10,000 copies/ml 
while 18 (72%) of the patients had CMV DNA values above 10,000 copies/ml.  
 
CMV IE-mRNA measurement: 
Of 25 patients, CMV IE-mRNA was monitored during periods of reactivation for 15 
patients. 7 patients showed detectable mRNA levels during reactivation. The mRNA 
levels were quantitated and the copy numbers are represented as copies per number of 
cells. The cell numbers were determined based on ERV-3 levels in the stored PBMC 
samples. 
 The time points at which mRNA tested positive for these patients are represented in the 
graphs below. The X axis represents the points in time when the samples were collected, 
Y axis represents the CMV DNA values in log copy numbers and the RNA values are 
represented in boxes on the graph. 
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CMV IE-mRNA detection: 
Seven patients (46.6%) of the 15 patients tested for IE-mRNA showed detectable mRNA 
levels.  
Characteristics of 7 patients who had detectable IE-mRNA: 
Pt 
no: 
Age Sex Diagnosis 
CMV 
Sero-
status 
(IgG) 
Day of 
first 
positive 
DNA 
Day of 
first 
positive 
mRNA 
Peak CMV 
DNA values 
(copies/ml) 
Peak CMV 
mRNA 
values 
(copies/10 
cells) 
CS12 M 47 AML +ve 23 30 1,57,555 9.76 
CS28 M 5 FA +ve 34 47 19,763 35,178.27 
CS49 F 47 AML +ve 30 30 1,67,499 51,677.73 
CS63 F 27 ALL +ve 23 27 2,666 15,428.09 
CS74 M 2 TM +ve 51 54 93,871 20,259.29 
CS84 M 36 AA +ve 44 51 19,298 102.86 
CS94 M 18 TM +ve 30 27 40,829 1,719.46 
 
 
Time of detection of IE-mRNA: 
Table 1: Table depicting the characteristic features of patients with detectable CMV 
IE-mRNA levels. AML – Acute Myeloid Leukemia; FA – Fanconi Anemia; ALL – 
Acute Lymph id Leuke ia; A – Aplastic Anemia; TM – Thalassemia major 
IE-mRNA was detectable in all patients after CMV DNA was detected except for one 
patient in whom CMV IE-mRNA was detected 3 days before DNA levels were detected. 
All the patients showed detectable mRNA levels while their CMV DNA levels were 
increasing in the initial phase of reactivation. Only one patient had detectable CMV IE-
mRNA while the CMV DNA level was declining. However this patient also showed an 
increase in the CMV DNA level one week later 
 
Peak CMV DNA values for RNA positive samples: 
Study number DNA level ( copies/ml) 
CS12 1,57,555 
CS28 19,763 
CS49 1,67,499 
CS63 2,666 
CS74 93,871 
CS84 19,298 
CS94 40,829 
 
Mean HCMV DNA values for these patients: 71,640.14 
 
 
 
 
 
Peak CMV DNA values for RNA negative values: 
Study number DNA level ( copies/ml) 
CS1 22,230 
CS2 3,527 
CS5 16,456 
CS8 4,721 
CS11 6,853 
CS24 60,045 
CS33 7,561 
CS39 4,81,482 
 
Mean CMV DNA values for these patients: 75,359.37 
 
There was no significant difference between the mean peak CMV DNA values of the 
patients who tested positive for CMV IE-mRNA and the patients who tested negative for 
CMV IE-mRNA. 
 
 
 
 
Limit of detection of CMV IE-mRNA RT-qPCR: 
The copies detected by the RT-qPCR for the IE-mRNA are depicted below. 
Copy numbers  
(copies/ml) 
Day 1 Day 2 Day 3 
3000 3053 773 5879 
3000 4885 1153 1234 
3000 2598 3448 3065 
300 Not detected 1662 963 
300 1849 Not detected Not detected 
300 1227 290 Not detected 
30 Not detected Not detected Not detected 
30 Not detected Not detected Not detected 
30 Not detected Not detected Not detected 
 
The limit of detection of the assay was calculated by calculating the mean of the values 
detected in the lowest dilution in the three separate occasions. The lower limit of 
detection of the assay was determined to be 1198 copies/ml. 
 
 
  
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
DISCUSSION 
Hematopoietic stem cell transplantation has evolved to be a life changing mode of 
therapy for malignancies and non-malignant conditions like thalassemia major and 
aplastic anemia. CMV is a major viral opportunistic pathogen in bone marrow transplant 
patients in the post-transplant period. Monitoring for CMV reactivation by CMV DNA 
PCR in the post transplant period is an essential investigation performed in the post 
transplant period. However no consensus is available on the CMV DNA levels at which 
preemptive therapy should be initiated for such patients. Moreover the drug of choice for 
preemptive therapy is now ganciclovir which in itself is a bone marrow toxic drug (144). 
The other major concern with ganciclovir therapy is the emerging trends of resistance of 
CMV to this drug, leaving the physicians with limited options for therapy (145).  
We evaluated the efficiency of the use of CMV IE-mRNA as a new marker of CMV 
reactivation in bone marrow transplant patients in the post transplant period. Earlier 
studies conducted on the use of CMV IE-mRNA as a marker met with problems such as 
false positivity with CMV DNA. This problem was alleviated by subjecting the RNA 
extracts with DNase enzyme before performing the reverse transcriptase PCR. Patients 
who underwent HSCT in our hospital were enrolled into our study. CMV reactivation in 
these patients was monitored by measuring their CMV DNA levels in whole blood using 
real- time PCR. CMV IE-mRNA levels were looked for in reactivators using real-time 
reverse transcriptase PCR.   
A total of 162 patients were enrolled into the study. Among them 77 patients (47.5%) 
belonged to the pediatric age group and 110 of them were male patients. The major 
malignant condition for which transplantation was done was acute myeloid leukemia and 
the major non malignant condition was thalassemia major. The donor group comprised 
mainly of matched unrelated donors and peripheral blood stem cells were the major graft 
source. 
The epidemiology of CMV infection varies with geographical regions and studies from 
India show that the viral infection is highly endemic in the subcontinent. The CMV 
serostatus of the patients before transplantation correlates with national statistics with 
95% showing elevated CMV IgG values, indicating past exposure to the virus. Only eight 
patients (5%) tested negative for both CMV IgM and IgG.  
According to global statistics, 60–70% of patients undergoing bone marrow 
transplantation with high risk factors undergo CMV reactivation in the post-transplant 
period. However, in our study, only 35 of 162 (21.6 %) of the study population had CMV 
reactivation during the study period. Among the 35 reactivators, 33 patients were CMV 
seropositive even before transplantation. 2 patients were CMV seronegative before 
transplantation.  
 Indian data regarding the rate of reactivation of CMV in HSCT patients is limited and 
one study conducted by Finny G J et al in 2001 records a reactivation rate of 42.8% of 31 
patients studied. The data from our study reveals a low rate of reactivation in this group 
of patients as compared to Western data and it may be attributed to the presence of 
neutralizing antibodies (anti gB/AD-1) in patients who did not develop the disease (151). 
In another study conducted by Finny et al in Indian renal transplant patients, similar 
findings were noted. The study revealed a higher incidence of neutralizing anti gB/AD-1 
antibodies along with high avidity CMV anti-IgG antibodies in patients who did not 
develop CMV reactivation in the post transplant period as opposed to the patients who 
reactivated (152). 
 Another possibility to be considered is the prevalent genotypes in the Indian population. 
Many studies have been conducted in developed countries on the prevalent genotypes of 
CMV and the impact they have on the outcome of patients in the post-transplant period 
(153,154). However, extrapolation of such data to the Indian population may not be 
accurate as the seroprevalence to the virus is high in India compared to developed 
nations. Genotype association studies have been conducted in the Indian subcontinent on 
perinatal and congenitally acquired CMV infection in neonates (155,156). The study 
conducted by Gandhoke et al on symptomatic infants in Delhi showed that the prevalent 
genotypes found in these infants were gB 1, 2 and 3. Genotype gB 3 was the more 
frequently isolated genotype from symptomatic infants (156). However no such data is 
available on HSCT patients from the Indian subcontinent.  
Among the reactivators, 92% reactivated in the engraftment period established to be the  
post-transplant period when patients are most susceptible to CMV reactivation . This has 
been attributed to poor cell mediated immunity seen in patients during this period. Only 
two patients showed increased viral loads in the pre-engraftment period.  
The CMV DNA level which indicates a “true” CMV infection has not been determined; 
the cutoff level at which preemptive therapy is initiated in our hospital currently is 1000 
copies/ml. Of 25 patients, 7(28%) consistently showed CMV DNA values below 10,000 
copies/ml while 18 (72%) had CMV DNA values above 10,000 copies/ml. Several 
studies have established cutoffs from 1,000 to 10,000 copies/ml of CMV DNA for 
initiation of preemptive therapy. The values depend on a number of factors and can vary 
depending on the seroprevalence of CMV in the respective geographical regions and the 
assay used to determine the CMV DNA levels (11). However there remains the need to 
establish an accurate cutoff for initiation of preemptive therapy.  
The CMV IE-mRNA PCR was preliminarily performed for 15 patients and 7(46.6%) 
patients showed detectable mRNA levels during reactivation. IE-mRNA was detectable 
in all patients after CMV DNA was detected except for one patient in whom CMV IE-
mRNA was detected 3 days before DNA levels were detected. The limit of detection of 
the assay was determined to be 1198 copies/ml. The low sensitivity of the assay may be 
attributed to this limit of detection of the assay. The lower limit of detection of mRNA 
should be improved so as to detect lower copy numbers of the mRNA. This could also be 
one of the reasons why the mRNA was detected only after the CMV DNA was detected. 
Another reason for the low sensitivity of the assay may be attributed to the alternate 
splicing mechanisms of the Immediate Early-1 region of the HCMV genome.  The 
splicing mechanisms at this region produce four different transcripts which are 
selectively produced at varying concentrations during the different steps of viral 
replication (27). Also the major spliced region of the mRNA that codes for the 72-kDa 
protein, which was the region of the genome that was targeted by our IE-mRNA assay, 
can further undergo varied splicing depending on the replication stage of the virus (26). 
The numerous splicing mechanisms present at this part of the viral genome may be 
responsible for the low sensitivity of this assay. 
All the patients showed detectable mRNA levels while their CMV DNA levels were 
increasing in the initial phase of reactivation. Only one patient had detectable CMV IE-
mRNA while the CMV DNA level was declining. However this patient also showed an 
increase in the CMV DNA level one week later. This finding reflects the fact that CMV 
IE- mRNA detection represents a true reactivation and if untreated can lead to CMV 
disease.  
The role of IE-mRNA as a potential marker of CMV reactivation cannot be ruled out. 
The assay developed in the study for detection of mRNA should be standardized further 
to detect lower copy numbers and the other splice variants should be considered to 
improve the sensitivity of the assay. 
  
 
 
 
LIMITATIONS OF THE STUDY 
1. The quality of RNA after extraction from PBMCs was not checked with UV 
spectrophotometric analysis.  
2. The lower limit of detection of the assay was assessed to be 1198 copies/ml and 
needs to be improved to be able to detect lower copies of the mRNA. 
3. Alternate splicing mechanisms of mRNA need to be addressed while designing 
primers and probes. Also the alternate splice variants should be checked for in 
patients who tested negative for the 72 kDa variant of this mRNA. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 
CONCLUSIONS 
 
The rate of reactivation of CMV in HSCT patients in our study was found to be 21.6%. 
This was surprisingly low compared to the Western data which records reactivation rates 
of 60-70%. 
Among 25 patients who were continuously monitored for CMV DNA levels, 7(28%) 
showed values which were consistently below 10,000 copies/ml.  
CMV IE-mRNA is an indicator of the reactivation of HCMV in bone marrow transplant 
patients in the post-transplant period. However the sensitivity of the IE-mRNA RT-qPCR 
needs to be improved so as to detect lower copies of the mRNA. 
Alternate splicing mechanisms of the IE-mRNA should be carefully evaluated to design 
primers and probes that ensure detection of all the splice variants by RT-qPCR. The 
alternate splice variants also need to be tested in the patients who were negative for the 
72kDa variant of the IE-mRNA. 
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ANNEXURE 
 
 
 
CMV STUDY CASE RECORD 
 
S. No: ………………………    Date: ……………….. 
Name:                                                             Hosp No:   
Age:   yrs Sex:    Diagnosis:   
Type of SCT: HSD/ HFD / MUD  Date of SCT:   
Type of conditioning:     Graft source: PBSC / BM 
Date of Neutrophil engraftment (ANC > 0.5 x 109/L):   
Date of Platelet engraftment (Plt > 20 x 109/L):   
Acute GVHD: Y / N  If Yes: Date on onset:  
Overall Grade of GVHD:  0-1 / II / III / IV 
CMV viremia: Y /  N  If Yes, Date on onset:   
CMV copies at diagnosis: ……… copies 
Randomization: Y / N; Date of randomization: …../…../…….. 
Group randomized into:  I  /  II 
Anti-viral therapy started: Ganciclovir / Foscarnet / Cidofovir 
Date of starting treatment:          Date of stopping treatment:   
Outcome of Rx: Complete resolution/ Partial resolution/ Developed CMV disease/ Died 
CMV disease: Y/N; Ste:  Lungs/GIT / CNS / BM / Liver;    Date of Dx: …../……/……… 
Relapse of CMV: Y / N;  Date of relapse:   
Present status: Alive / Death If dead, cause – GVHD / infection / CMV / Relapse  
M F 
……../……/……….. 
…../……/……….. 
…../……/……….. 
…../……/……….. 
…../……/……….. …../……/……….. 
…../……/……….. 
…../……/……….. 
                                       Department of Haematology & Department of Clinical Virology 
Christian Medical College, 
Vellore, 632 004 
 
Assent Form 
 
Title of Study:  
 
A study of the kinetics of CMV viremia in patients undergoing bone marrow transplantation and 
identification of cutoffs for initiation of ganciclovir therapy in patients who show reactivation of CMV 
infection  
 
Principal investigators: 
 
Dr Rayaz Ahmed, Assistant Professor, Clinical Haematology                                          
Dr. Sangeeta Susan Thomas, PG Registrar, Microbiology 
Dr. Biju George, Professor Clinical Haematology 
Dr. Asha Mary Abraham, Professor Clinical Virology 
 
Why are we doing this study? 
 
You have been asked to participate in a research study. One of the major complications that can occur 
after bone marrow transplant is a viral infection called as Cytomegalovirus. This infection can involve the 
lungs and/or the liver and intestines and is difficult to treat. Normally we try to detect this virus in the 
blood and start treatment before it involves the organs of the body. However, the medicines used to 
treat this infection are costly and causes a number of side effects most importantly a decrease in all the 
blood counts leading to infection and bleeding. 
  
Normally we start treatment at very low levels of virus. This may not be required and it may be safe to 
start treatment only when the levels rise. This study is aimed at finding out if it is reasonable to start 
treatment only after the levels have increased. This means that in a number of people, treatment with 
this costly medicine can be avoided and the side effects can also be avoided.  
 
 
What will happen during the study? 
 
You will be monitored after transplant with blood samples to look for evidence of viral infection. This is 
done routinely for all patients after transplant. You will be included in the study only if the tests for CMV 
come positive. If you consent for the study, you will either be started on a medicine called ganciclovir 
once the levels rise beyond 1000 copies or your levels will be monitored and medicine started only once 
the levels have increased beyond a specified level. You will be monitored serially with blood samples to 
look for improvement in the levels.  
 
Are there good things and bad things about the study? 
If you are randomized into the arm where the levels are monitored, it is possible that you may not 
require treatment at all. 
This will help in reducing the cost and side effects associated with this treatment. 
 
There is a worry whether by waiting there is a possibility of the viral infection affecting various organs. 
You will be monitored very closely while on follow up and treatment can be started at any time.  
 
 
Who will know about what I did in the study? 
If you are a part of this study your name and address will not be given to anyone without your consent 
unless required by law.  If you would like, results of this study will be made available to you when it is 
finished.  
 
Can I decide if I want to be in the study? 
You have every right to decide whether you want to participate in this study. Nobody will be angry or 
upset if you do not want to be in the study. We are talking to your parents/ legal guardians about the 
study and you should talk to them about it too. If you do not take part in this study, you will be treated 
with our standard practice that is to start the medicine as soon as the levels go beyond 1000 copies/ml. 
 
 
Assent: 
 
 
I was present when………………………………………………………….. read this form and gave his/her verbal assent. 
 
 
 
 
 
 
Signature/ Thumb impression     Date 
 
 
 
______________________________         ___________________     ________________ 
Name of person who obtained consent                  Signature                              Date 
 
 
 
 
  INFORMED CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
Investigator: Dr. Biju George   
 
Study Title: A study of the kinetics of CMV viremia in patients undergoing bone marrow 
transplantation and identification of cutoffs for initiation of ganciclovir therapy in patients who show 
reactivation of CMV infection.  
 
Protocol Number:  
 
Subject /Parent Initials: 
__________________ 
Subject Number: 
__________________ 
Subject Birth Date: 
_____________ 
 
 
INTRODUCTION 
You are being asked to take part in a research study. This research study gathers information about a 
new type of treatment. Dr. Biju George is the primary person conducting the study.  
 
You will take part in the study only if you want to.  It is important that you have the information about 
this study that you need in order to decide if you want to participate. Dr. Biju George will talk to you 
about the study, and answer your questions. Please take your time making your decision.  
 
This study has been approved by an ethics committee.The ethics committee helps protect subjects in 
research studies. 
 
This study involves starting treatment with a medicine for a viral infection called 
cytomegalovirus (CMV) at different time points when the test becomes positive. This study will 
attempt to answer whether this modification will reduce the amount of people who require 
treatment for this infection and others in future may benefit from the information learned in 
this study.  
Approximately 70 subjects will take part in this study.  Your participation in this study will last 
for approximately  3 months after your transplant, the side effects are acceptable, and the 
investigator believes it is in your best interest. 
 
PURPOSE OF THE STUDY 
You are being asked to take part in this study because approximately 50% of patients who have an 
allogeneic transplant will develop a viral infection called CMV. We check for this infection routinely in all 
patients using a blood test called as PCR. If the test is positive, you are routinely started on a drug called 
as ganciclovir to reduce the infection. This medicine however has a number of side effects importantly a 
rapid reduction in blood counts. In some patients, this infection may improve by itself if the immune 
system of the body controls it. Hence in many hospitals, doctors may wait to see if the levels rise before 
starting this treatment. The purpose of this study is to see whether starting this treatment later will help 
in reducing the number of persons who will require this treatment.  
 
TEST ARTICLE 
Nil 
 
STUDY PROCEDURES 
You will be asked to sign this informed consent form before any further treatment is given.  
If the PCR test for CMV becomes positive, you need to receive a drug called as ganciclovir. You 
will receive this drug either as soon as the test becomes positive or when the levels increase.  
You will be monitored regularly after starting treatment to look for recovery from the infection. 
The medicine will be stopped after 14 days of treatment once the PCR is negative. You will be 
followed up regularly after stopping the medicine to look for any symptoms of this disease 
coming back again.  
ACTIVE STUDY PERIOD 
The study covers a period of 3 months following transplant. You may ask if you have any 
clarification. 
RISKS 
Infection with CMV generally involves the blood but in 10% of patients it can affect the lungs, 
liver or the stomach. The medicine is aimed at reducing the chance of involvement of these 
organs in the body. We do not think that by starting the medicines later, there will be a higher 
risk. The medicines on the other hand can cause a marked reduction in blood counts in more 
than 50 -60% of patients. This can leading to infections and bleeding.  
 
BENEFITS ASSOCIATED WITH THE STUDY 
The number of people who will need treatment for CMV infection will be lower and this will 
lead to a lesser number of side effects. Others may benefit from the information learned in this 
study.  
ALTERNATIVES TO PARTICIPATION  
We will continue to treat as soon as the PCR becomes positive which is our standard practice.  
 
CONFIDENTIALITY 
Your records from the study are confidential unless law requires certain people to see them.    
Your name or identifying information will not be used in reports or publications resulting from 
this study.   
PAYMENT OR REIMBURSEMENT 
 
Nil 
 
PAYMENT FOR TREATMENT OF RESEARCH-RELATED INJURY 
Nil 
 
COSTS 
You will not have any additional costs as a participant in this study. 
 
LIMITS OF FINANCIAL COMPENSATION 
Nil 
 
CONTACTS 
If you have questions about your rights as a research subject, please call Dr. L. Jeyaseelan, Member 
Secretary, Ethics Committee or Dr. Nihal Thomas, Deputy Chairperson, Research & Ethics Committees at 
+91-416-2284294 
 
If you have questions about this study or if you think you have had an injury related to your participation 
in this study and you want information on treatment, please call Dr. Biju George  +91-416-2282169  
 
VOLUNTARY PARTICIPATION 
Your participation in this study is voluntary.  You do not have to agree to participate.  If you do not take 
part in this study, you treatment will continue as is our standard practice.  
 
CONSENT 
Information describing this research study has been explained to me. I have read and 
understood this consent form. All my questions have been answered to my satisfaction. I 
voluntarily consent for my son/daughter to participate in this research study and to the release 
of my medical records as described in this form.  
I do not give up my legal rights by signing this consent form. I will receive a signed and dated 
copy of this consent form. 
 
 
 
Study Title: A study of the kinetics of CMV viremia in patients undergoing bone marrow 
transplantation and identification of cutoffs for initiation of ganciclovir therapy in patients who show 
reactivation of CMV  
 
Study Number:  
 
Name of Study Doctor:   _________________________ 
 
Patient Number/Initials:               _________/_______________ 
 
Date of Birth / Age:                     _________________________ 
 
Patient Name:                             _________________________ 
 
Parent/Legal guardian’s  Name:        _________________________ 
                     
  
Please initial Box 
(Subject) 
1 
 
I , _______________________, have read and understood the preceding 
information describing this research study and my questions have been 
answered to my satisfaction. I voluntarily consent to my son/daughter to  
participate in this research study and to the release of my medical records as 
set forth under the “Confidentiality” section. 
 
(                  ) 
2 
 
I have received /will receive a copy of the signed Patient Information/ 
Informed   Consent. 
 
(                  ) 
3 
 
I understand that my son’s/daughter’s participation is voluntary and that 
he/she is free to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
(                  ) 
4 
 
I understand that the investigators, the Ethics Committee and regulatory 
authorities will not need my permission to look at my son’s/daughter’s health 
records in respect of the current study and any further research that may be 
conducted in relation to it, even if he/she withdraws from the trial. I agree to 
this access. However, I understand that my son’s/daughter’s identity will not 
be revealed in any information released to third parties or published. 
 
(                  ) 
5 
 
I agree to the transfer of my son’s/daughter’s personal anonymized data to 
other countries in accordance with local laws and guidelines 
(                  ) 
6 
 
I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) 
(                  ) 
 
7 
 
I agree for my son/daughter to take part in the above study. 
(                  ) 
 
______________________ 
 
_________________ 
 
_____________ 
Name of Patient Signature of the parent    Thumb impression 
 /legal guardian* 
Date of Signature 
 
______________________ 
 
______________________ 
 
_____________ 
Name of Study Doctor Signature Date of Signature 
 
 
 
 
(* If a patient has limited ability to read and write, an impartial witness should be present 
during the entire informed consent discussion and his/her legally acceptable representative 
should sign on patient’s behalf). In these instances the patient places his/ her left thumb 
impression in the place of the signature.  
 
 
 
Patient’s Legally Acceptable Representative’s Statement:                                      NA 
I, as the patient’s legally acceptable representative, was present during the consenting 
procedure and understand the preceding information describing this study.  All of the 
questions regarding the study and the patient’s participation in it have been answered to my 
satisfaction and that of the patient.  I state that all aspects of the study were clearly presented 
during the consent procedure.  The patient is willing to participate in the study and I sign below 
on his/her behalf testifying to this effect.   
Name of the Patient: __________________________________________________________ 
Name of the Legally Acceptable Representative: ____________________________________ 
Relationship to the Patient: ______________________________ 
Signature of the Legally Acceptable Representative:__________________________________ 
Date and signature:______________________________ 
Witness Declaration of Patient's Informed Consent                                                  NA 
By signing the consent form I attest that the information was accurately explained to and 
apparently understood by the patient and the legally acceptable representative (if applicable) 
and that informed consent was freely given by the patient.  
(* A witness is not required unless the subject is unable to read (e.g. blind or illetrate) or unless 
indicated in the protocol. If a witness is present, the witness must observe the entire informed 
consent process). 
Date ___________________                     Signature ____________________________ 
                                         (Impartial Witness) 
Name of Witness:         ____________________________ 
Address of Witness: _____________________________ 
                          _____________________________ 
Comments: 
 ____________________________________________________________ 
  
 ____________________________________________________________ 
  
 ____________________________________________________________ 
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Study no: Age Sex Hospital no: Diagnosis Pre-trnsplnt cmv dnaDt of trnsplnt Wk 1 Wk 2
CS1 12 M 132729F Acute Leukemia 25/7/2012 27/7/2012 1/8/2012 9/8/2012
NEG
CS2 12 F 812122D Thalassemia Major 26/7/2012 1/8/2012 4/8/2012 13/8/2012
NEG NEG
CS5 20 M 698750C
Fanconi Anemia with 
MDS 30/7/2012 4/8/2012 7/8/2012 13/8/2012
NEG NEG
CS8 50 M 197848F AML M4 13/8/2012 17/8/2012 20/8/2012 27/8/2012
NEG NEG
CS11 32 F 208315F AML 20/8/2012 23/8/2012 27/8/2012 3/9/2012
NEG NEG
CS12 47 M 146223F AML 20/8/2012 24/8/2012 27/8/2012 3/9/2012
NEG NEG
CS16 13 M 012158F Thalassemia Major 23/8/2012 29/8/2012 3/9/2012 10/9/2012
NEG NEG
CS21 5 M 854928D Thalassemia Major 10/9/2012 17/9/2012 17/9/2012 24/9/2012
NEG 1974
CS24 16 F 257096F AML-M1 17/9/2012 21/9/2012 24/9/2012 1/10/2012
NEG NEG
CS28 5 M 929189D Fanconi Anemia 24/9/2012 30/9/2012 1/10/2012 8/10/2012
NEG NEG
CS33 18 F 270704F AML 8/10/2012 11/10/2012 15/10/2012 22/10/2012
NEG NEG
CS39 32 M 325017D ALL 18/10/2012 25/10/2012 1/11/2012
NEG NEG
CS43 15 M 111409F Thalassemia Major 29/10/2012 2/11/2012 5/11/2012 12/11/2012
NEG NEG
CS51 35 F 157226D ALL 12/11/2012 15/11/2012 19/11/2012 26/11/2012
NEG NEG
CS61 50 M 321898F AML 3/12/2012 7/12/2012 10/12/2012
NEG
CS49 47 F 281462F AML M1 8/11/2012 14/1/2012 10/1/2013 17/1/2013
NEG NEG
CS63 27 F 223319F ALL 10/12/2012 14/12/2012 17/12/2012 24/12/2012
NEG NEG
CS69 1 M 924418D Thalassemia Major 24/12/2012 31/12/2012 3/1/2013 10/1/2013
1741
CS71 22 M 178570F ALL 31/12/2012 5/1/2013 7/1/2013 14/1/2013
NEG NEG
CS72 15 M 159795F Aplastic anemia 3/1/2013 8/1/2013 10/1/2013 17/1/2013
NEG NEG
CS74 2 M 714847D Thalassemia Major 7/1/2013 14/1/2013 17/1/2013 24/1/2013
NEG NEG
CS84 36 M 370602F Aplastic anemia 8/2/2013 11/2/2013 18/2/2013
NEG NEG
CS94 18 M 575868C Thalassemia Major 25/2/2013 1/3/2013 4/3/2013 11/3/2013
NEG NEG
CS88 6 F 345821F ALL 14/2/2013 21/2/2013 28/2/2013
NEG NEG
CS93 11 M 217647F Thalassemia major 21/2/2013 28/2/2013 7/3/2013
NEG NEG
Wk 3
13/8/2012 30/8/2012 3/9/2012 6/9/2012 10/9/2012 17/9/2012 20/9/2012
NEG NEG 570 NEG NEG 22230 73636
30/8/2012 3/9/2012 6/9/2012 10/9/2012 13/9/2012 17/9/2012 20/9/2012 24/9/2012 27/9/2012
NEG 1152 3527 3220 3496 NEG NEG
20/8/2012 29/8/2012 30/8/2012 3/9/2012 7/9/2012 10/9/2012 13/9/2012 17/9/2012 20/9/2012 24/9/2012 27/9/2012
NEG 3764 21563 10123 24503 11497 16456 NEG NEG NEG NEG
3/9/2012 6/9/2012 13/9/2012 20/9/2012 24/9/2012 27/9/2012 1/10/2012 4/10/2012 8/10/2012
NEG NEG 977 2850 4721 2704 NEG NEG
8/9/2012 17/9/2012 20/9/2012 24/9/2012 27/9/2012 1/10/2012 4/10/2012 8/10/2012 11/10/2012 15/10/2012
NEG NEG 546 6853 1268 3861 6620 NEG NEG
10/9/2012 17/9/2012 20/9/2012 24/9/2012 27/9/2012 1/10/2012 4/10/2012 8/10/2012 11/10/2012 15/10/2012 18/10/2012
NEG 11492 NEG 1749 6453 24665 66343 44279 14962 157555 29371
17/9/2012 24/9/2012 27/9/2012 1/10/2012 4/10/2012 8/10/2012 11/10/2012 15/10/2012 18/10/2012 22/10/2012 25/10/2012
NEG NEG NEG 5006 NEG 2438 6648 NEG NEG NEG NEG
1/10/2012 11/10/2012 15/10/2012 18/10/2012 22/10/2012 25/10/2012 29/10/2012 1/11/2012 5/11/2012
NEG 1241 5948 13994 44254 46707 11846 23477
8/10/2012 13/10/2012 18/10/2012 22/10/2012 25/10/2012 29/10/2012 1/11/2012 5/11/2012 8/11/2012 15/11/2012
NEG NEG NEG NEG 559 300 6561 60045 1084 4290
15/10/2012 18/10/2012 22/10/2012 29/10/2012 1/11/2012 5/11/2012 8/11/2012 12/11/2012 15/11/2012 19/11/2012
NEG NEG 4592 264 4046 2978 19763 15625 357
29/10/2012 5/11/2012 8/11/2012 12/11/2012   15/11/2012 19/11/2012 22/11/2012 26/11/2012 29/11/2012 3/12/2012 6/12/2012
NEG 1515 445 4454 7561 345 NEG NEG NEG NEG NEG
10/11/2012 13/11/2012 15/11/2012 19/11/2012 22/11/2012 26/11/2012 29/11/2012 3/12/2012 6/12/2012 10/12/2012 13/12/2012
NEG NEG NEG 2767 7049 481482 16543 31790 68584 46251 18741
22/11/2012 29/11/2012 6/12/2012 10/12/2012 13/12/2012 17/12/2012 20/12/2012 24/12/2012 27/12/2012 31/12/2012
NEG NEG 240 31524 37679 156348 97305 35002 99585
10/12/2012 13/12/2012 17/12/2012 20/12/2012 27/12/2012 31/12/2012 3/1/2012 7/1/2013 10/1/2013
NEG 5589 8608 NEG NEG 3125 20800 NEG NEG NEG
17/12/2012 24/12/2012 31/12/2012 3/1/2013 7/1/2013 10/1/2013 14/1/2013 21/1/2013 24/1/2013
NEG NEG NEG 5011 819 NEG 21848 12622 2416
24/1/2013 31/1/2013 7/2/2013 11/2/2013 14/2/2013 18/2/2013 21/2/2013 25/2/2013 28/2/2013 4/3/2013
NEG 10922 4014 85633 4212 167499 8054 7752 130147
Wk 4 Wk 5 Wk 6 Wk 7 Wk 8
31/12/2012 10/1/2013 14/1/2013 17/1/2013 21/1/2013 24/1/2013 28/1/2013 31/1/2013 4/2/2013 7/2/2013
NEG 703 2272 2666 984 642 946 NEG 2369 NEG
17/1/2013 24/1/2013 28/1/2013 4/2/2013 7/2/2013 11/2/2013 14/2/2013 18/2/2013 21/2/2013 25/2/2013
8101 4988 NEG NEG NEG NEG NEG NEG NEG
21/1/2013 28/1/2013 31/1/2013 4/2/2013 7/2/2013 11/2/2013 14/2/2013 18/2/2013 21/2/2013 25/2/2013 28/2/2013
NEG NEG 7735 46902 7577 7909 21084 14201 588
24/1/2013 31/1/2013 4/2/2013 7/2/2013 11/2/2013 14/2/2013 18/2/2013 21/2/2013 25/2/2013
NEG NEG 2488 8561 29096 409 1985 3524
31/1/2013 7/2/2013 11/2/2013 14/2/2013 18/2/2013 21/2/2013 25/2/2013 28/2/2013 4/3/2013 7/3/2013 11/3/203
NEG NEG NEG NEG NEG NEG NEG NEG NEG 2161 33208
25/2/2013 28/2/2013 4/3/2013 7/3/2013 11/3/2013 18/3/2013 21/3/2013 25/3/2013 28/3/2013 1/4/2013
NEG NEG NEG NEG NEG NEG 1142 19298 409 NEG
18/3/2013 21/3/2013 25/3/2013 28/3/2013 1/4/2013 4/4/2013 8/4/2013 11/4/2013 15/4/2013 18/4/2013 22/4/2013
NEG NEG NEG 142 1086 NEG 7061 40829 137 101 2229
7/3/2013 11/3/2013 14/3/2013 18/3/2013 21/3/2013 25/3/2013 28/3/2013 1/4/2013 4/4/2013 8/4/2013 11/4/2013
NEG NEG NEG 3518 NEG 28998 661 156 NEG 3565 NEG
14/3/2013 21/3/2013 25/3/2013 28/3/2013 1/4/2013 4/4/2013 8/4/2013 11/4/2013 18/4/2013 22/4/2013
NEG NEG NEG 35799 547 2040 10349 1928 NEG
25/9/2012 29/9/2012 1/10/2012 4/10/2012 8/10/2012 11/10/2012 15/10/2012 22/10/2012
30722 8114 18673 854 NEG NEG NEG NEG
1/10/2012 4/10/2012 9/10/2012 11/10/2012 15/10/2012 18/10/2012 22/10/2012 25/10/2012
NEG NEG NEG NEG NEG NEG NEG NEG
1/10/2012 4/10/2012 8/10/2012 11/10/2012 15/10/2012 18/10/2012
NEG NEG NEG NEG NEG NEG
11/10/2012 15/10/2012 18/10/2012
NEG NEG NEG
18/10/2012 25/10/2012 29/10/2012 1/11/2012 5/11/2012 8/11/2012
NEG NEG NEG NEG NEG NEG
22/10/2012 25/10/2012 29/10/2012 1/11/2012 5/11/2012 15/11/2012
4417 8340 NEG 490 NEG
29/10/2012 1/11/2012 5/11/2012 8/11/2012 12/11/2012 15/11/2012 19/11/2012 22/11/2012
NEG NEG NEG NEG NEG NEG NEG NEG
8/11/2012 12/11/2012 15/11/2012 19/11/2012 22/11/2012 26/11/2012 29/11/2012 3/12/2012
2165 173 NEG 166 NEG 164 NEG NEG
22/11/2012 26/11/2012 29/11/2012 3/12/2012
NEG NEG NEG
22/11/2012 26/11/2012 29/11/2012
6783 1495 NEG
10/12/2012 17/12/2012 9/1/2013
NEG NEG NEG
17/12/2012 20/12/2012 24/12/2012 27/12/2012 31/12/2012 3/1/2013
1546 NEG NEG NEG NEG NEG
7/1/2013 14/1/2013 17/1/2013 21/1/2013 28/1/2013
113 NEG NEG NEG NEG
14/1/2013 17/1/2013 21/1/2013 24/1/2013 7/2/2013
NEG NEG NEG NEG NEG
28/1/2013 31/1/2013 4/2/2013 7/2/2013 11/2/2013 14/2/2013
NEG NEG NEG NEG NEG NEG
7/3/2013 11/3/2013 14/3/2013 18/3/2013 25/3/2013
24616 NEG NEG NEG
Wk 9 Wk 10 Wk 11 Wk 12
14/2/2013 18/2/2013
NEG NEG
28/2/2013
NEG
4/3/2013 7/3/2013 11/3/2013 14/3/2013 18/3/2013 21/3/2013 25/3/2013 28/3/2013
2334 1163 2217 722 10705 5838 NEG 83
7/3/2013 11/3/2013 18/3/2013 25/3/2013 1/4/2013 4/4/2013
324 8202 2121 NEG 1716 NEG
14/3/2013 18/3/2013 21/3/2013 25/3/2013 28/3/2013 1/4/2013 4/4/2013 8/4/2013
93871 46179 19321 14063 NEG NEG NEG NEG
4/4/2013 8/4/2013 11/4/2013 15/4/2013 18/4/2013 22/4/2013 25/4/2013 29/4/2013
NEG 2263 NEG NEG NEG NEG NEG NEG
25/4/2013 29/4/2013 6/5/2013
151 362 NEG
15/4/2013 18/4/2013 22/4/2013 25/4/2013 29/4/2013 2/5/2013 6/5/2013 9/5/2013
NEG NEG NEG NEG NEG NEG NEG NEG
25/4/2013 29/4/2013 2/5/2013 6/5/2013 13/5/2013 20/5/2013
NEG NEG NEG NEG
